<!DOCTYPE html>
<html lang="en">
<head>
  <title>
    eCFR :: 21 CFR Part 50 -- Protection of Human Subjects
  </title>

  <link rel="canonical" href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50" />

  <link rel="apple-touch-icon" sizes="180x180" href="/assets/favicon/apple-touch-icon-18ac1159c2217e79fb45c21adc630384b65af33c4e6de8eca0ff8527a4fe080e.png">
<link rel="icon" type="image/png" sizes="32x32" href="/assets/favicon/favicon-32x32-601e211398bdd3b5d26f99ae1ddae16e940b6a6223cb83f429419e6709f596f2.png">
<link rel="icon" type="image/png" sizes="16x16" href="/assets/favicon/favicon-16x16-8e7cf46953c8eadd70c27e99d2977556a7ad517c1d809782451b24be80323d14.png">
<link rel="manifest" href="/assets/favicon/site-17bc871d6b501401cd30d1f57e54a581f21f9c964717dd77d28e6f026da4b560.webmanifest">
<link rel="mask-icon" href="/assets/favicon/safari-pinned-tab-42724ccbb4192754e3500f02bee26d07b1c8432d7179433dd34d8d59c4e0882b.svg" color="#fab827">
<link rel="shortcut icon" href="/assets/favicon/favicon-014ef9fe5cc7969da15185d0790dba54c9c41bbcedda5477f9a7214d98263525.ico">
<meta name="msapplication-TileColor" content="#ffc40d">
<meta name="msapplication-config" content="/assets/favicon/browserconfig-d9fe2961ea6e1d05b91dec740f2c7b3b916c646691e7c909c258dea3ad28cd94.xml">
<meta name="theme-color" content="#ffffff">


    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script src="/assets/google_analytics-a2da3bb5c78c39ec6f425a2de69612f49200191a66f6aaac3b373bc53618cf0e.js" async="async" nonce="AUTGbSXz4HJat8kQoVIVoQ=="></script>

    <!-- We participate in the US government's analytics program. See the data at analytics.usa.gov. -->
    <script async type="text/javascript" nonce="AUTGbSXz4HJat8kQoVIVoQ==" src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=NARA&subagency=fedreg" id="_fed_an_ua_tag"></script>

  <link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link
href="https://fonts.googleapis.com/css2?family=Roboto:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,700&family=Bitter:ital,wght@0,400;0,500;0,700;1,400;1,500;1,700&display=swap"
rel="preload"
as="style">
<link
href="https://fonts.googleapis.com/css2?family=Roboto:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,700&family=Bitter:ital,wght@0,400;0,500;0,700;1,400;1,500;1,700&display=swap"
rel="stylesheet">


  <link rel="stylesheet" media="all" href="/assets/vendor-ed1f17021e0f5e5ba9861e9a88550a0d17aa9657d0832f953e6156a822fe3a1d.css" data-turbo-track="true" />
  <link rel="stylesheet" media="all" href="/assets/application-cab3fe704abacf30de204627077d84af75f499a7a95a6ebf38ab9f441d80db4b.css" data-turbo-track="true" />
  <link rel="stylesheet" media="print" href="/assets/print-e85ef07360cd8210c510308470ec9745d5d7b31065d9007a9d9b6935c561c232.css" data-turbo-track="true" />

  <script src="/assets/application_pipeline-662bba96b1118fe94244c70ca2c6a5043f8d3e1ea30f8a9d57d521ce1c692105.js" data-turbo-eval="false" async="async" defer="defer" nonce="AUTGbSXz4HJat8kQoVIVoQ=="></script>

  <script type="importmap" data-turbo-track="reload" nonce="AUTGbSXz4HJat8kQoVIVoQ==">{
  "imports": {
    "application": "/assets/application-335c9d0168c1b2a3960dd56fdf4f6c209d0eec1942adb72b6441483bed14e77f.js",
    "@hotwired/turbo-rails": "/assets/turbo.min-f971c8640d593387ea5afa6f0b3f51d9868c8ab3b4ddf1c811da0ed00d67af2d.js",
    "@hotwired/stimulus": "https://ga.jspm.io/npm:@hotwired/stimulus@3.2.2/dist/stimulus.js",
    "@hotwired/stimulus-loading": "/assets/stimulus-loading-6024ee603e0509bba59098881b54a52936debca30ff797835b5ec6a4ef77ba37.js",
    "@lodash/debounce": "https://ga.jspm.io/npm:lodash.debounce@4.0.8/index.js",
    "stimulus-autocomplete": "/assets/stimulus-autocomplete-0e2d350d1a0100abce1840193618fa0e606c0425d5631eb27dee0fb068cc32df.js",
    "stimulus-use": "https://ga.jspm.io/npm:stimulus-use@0.52.0/dist/index.js",
    "controllers/agencies_controller": "/assets/controllers/agencies_controller-b39755bd0bdc29806a7e88bb2015c8cb873f41228c3332df2a9a0b91e94af87c.js",
    "controllers/application": "/assets/controllers/application-e361dd5f2e228c2fb25a1549ad19f7ab2ee254e8123572f3fb9694ad08711254.js",
    "controllers/changes_controller": "/assets/controllers/changes_controller-7d46a5241e38838956e42fa95fe3b8a38901c1c5c739c623498328449cb8f6d1.js",
    "controllers/compare_controller": "/assets/controllers/compare_controller-d4c7c2f7183e9a0487fb4156d3be50ca77ced0e1881289fbe3b0920b4a88ec95.js",
    "controllers/element_controller": "/assets/controllers/element_controller-124c5e519399db700016351f28875d1aebd96b8966ef7655beb3e8ec42529c3e.js",
    "controllers/form_controller": "/assets/controllers/form_controller-521a8ae5e19bf25bcf358a35c386589c4ae49399968da815af3e5fedb4e66cad.js",
    "controllers": "/assets/controllers/index-075d84f1ecd1595c9ab3e04d66cb668dc9f6fb81d4809c437cbb0a5c0ec6fce2.js",
    "controllers/modal_controller": "/assets/controllers/modal_controller-b9cff36cd77bfb60e03304caa4eecacff19fc3713510141975d9e6f2748ac706.js",
    "controllers/placeholder_controller": "/assets/controllers/placeholder_controller-db5bbdf7df068e036eb77a730c74a68b59d680045962165deb575098d64ea172.js",
    "controllers/recent_changes_controller": "/assets/controllers/recent_changes_controller-b55783709d43d67c169ce404aad187bb8a49f140d816a203405cc382ae31d605.js",
    "controllers/suggestions_controller": "/assets/controllers/suggestions_controller-c86bd514065aba875525a390293adf8e27176ccdd869a92a035c06b027e67771.js",
    "controllers/timeline_controller": "/assets/controllers/timeline_controller-d797067edc737523ee3485893dd7f9f0e658d0e421b93ec3657bd7dcf6d9d1d2.js"
  }
}</script>
<link rel="modulepreload" href="/assets/application-335c9d0168c1b2a3960dd56fdf4f6c209d0eec1942adb72b6441483bed14e77f.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/turbo.min-f971c8640d593387ea5afa6f0b3f51d9868c8ab3b4ddf1c811da0ed00d67af2d.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="https://ga.jspm.io/npm:@hotwired/stimulus@3.2.2/dist/stimulus.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/stimulus-loading-6024ee603e0509bba59098881b54a52936debca30ff797835b5ec6a4ef77ba37.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="https://ga.jspm.io/npm:lodash.debounce@4.0.8/index.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/stimulus-autocomplete-0e2d350d1a0100abce1840193618fa0e606c0425d5631eb27dee0fb068cc32df.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="https://ga.jspm.io/npm:stimulus-use@0.52.0/dist/index.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/agencies_controller-b39755bd0bdc29806a7e88bb2015c8cb873f41228c3332df2a9a0b91e94af87c.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/application-e361dd5f2e228c2fb25a1549ad19f7ab2ee254e8123572f3fb9694ad08711254.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/changes_controller-7d46a5241e38838956e42fa95fe3b8a38901c1c5c739c623498328449cb8f6d1.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/compare_controller-d4c7c2f7183e9a0487fb4156d3be50ca77ced0e1881289fbe3b0920b4a88ec95.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/element_controller-124c5e519399db700016351f28875d1aebd96b8966ef7655beb3e8ec42529c3e.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/form_controller-521a8ae5e19bf25bcf358a35c386589c4ae49399968da815af3e5fedb4e66cad.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/index-075d84f1ecd1595c9ab3e04d66cb668dc9f6fb81d4809c437cbb0a5c0ec6fce2.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/modal_controller-b9cff36cd77bfb60e03304caa4eecacff19fc3713510141975d9e6f2748ac706.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/placeholder_controller-db5bbdf7df068e036eb77a730c74a68b59d680045962165deb575098d64ea172.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/recent_changes_controller-b55783709d43d67c169ce404aad187bb8a49f140d816a203405cc382ae31d605.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/suggestions_controller-c86bd514065aba875525a390293adf8e27176ccdd869a92a035c06b027e67771.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<link rel="modulepreload" href="/assets/controllers/timeline_controller-d797067edc737523ee3485893dd7f9f0e658d0e421b93ec3657bd7dcf6d9d1d2.js" nonce="AUTGbSXz4HJat8kQoVIVoQ==">
<script type="module" nonce="AUTGbSXz4HJat8kQoVIVoQ==">import "application"</script>

  

  <meta name="viewport" content="width=970">
  <meta name="format-detection" content="telephone=no">
    <meta name="dcterms.title"
    content="21 CFR Part 50 -- Protection of Human Subjects" />
	<meta name="dcterms.bibliographicCitation"
    content="21 CFR Part 50" />

  <meta property="og:title"
    content="21 CFR Part 50 -- Protection of Human Subjects" />
  <meta property="og:url"
    content="/current/title-21/part-50" />

  <meta property="ecfr:citationDate"
    content="" />


</head>
  <body data-environment="production" data-honeybadger-js-api-key="f722cff2" data-revision="fe90b535b988cdb7ef5a8c4f0a288eb096501233" data-google-ga4-tag="G-K7SMYBYX81" data-service="ecfr-web" data-domain=".ecfr.gov">

    <!-- Zendesk Form -->
      <div class="btn" id="feedbackbutton" type="button"><span class="icon-ecfr-chat"></span>Site Feedback</div>
      <div id="legacy_browser_modal" class="modal fade" role="dialog" aria-labelledby="genericModal" aria-hidden="true" tabindex="-1">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">You are using an unsupported browser
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
        <span aria-hidden="true">&times;</span>
        </h5>
      </div>
      <div class="modal-body">
        <p>
          You are using an unsupported browser. This web site is designed for the current versions of
          Microsoft Edge, Google Chrome, Mozilla Firefox, or Safari.
        </p>
      </div>
    </div>
  </div>
</div>

      <div id="interstitial-feedback-modal" class="modal fade in" aria-hidden="true" tabindex="-1" role="dialog" aria-labelledby="Feedback: Contact Us">
  <div class="modal-dialog" role="document">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">×</span>
        </button>
        <h3 class="text-center">Site Feedback</h3>
      </div>
      <div class="modal-body">
        <p>
          The Office of the Federal Register publishes documents on behalf of Federal agencies but does not have any authority over their programs. We recommend you directly contact the agency associated with the content in question.
        </p>
        <hr>
        <div class="row">
          <div id="website-feedback" class="col-xs-6 col-md-6 feedback-section">
            <p>
              If you have comments or suggestions on how to improve the www.ecfr.gov website or have questions about using www.ecfr.gov, please choose the 'Website Feedback' button below.
            </p>
            <div class="text-center">
              <a class="btn btn-primary btn-medium text-center" href="">
                <div><span class="icon-ecfr icon-ecfr-help "></span></div>
                Website Feedback
</a>            </div>
          </div>
          <div id="content-feedback" class="col-xs-6 col-md-6 feedback-section">
            <p>
              If you would like to comment on the current content, please use the 'Content Feedback' button below for instructions on contacting the issuing agency
            </p>
            <div class="text-center">
              <a class="btn btn-primary btn-medium text-center" href="">
                <div><span class="icon-ecfr icon-ecfr-legal "></span></div>
                Content Feedback
</a>            </div>
          </div>
        </div>
        <div class="text-center small-text">If you have questions for the Agency that issued the current document please contact the agency directly.</div>
      </div>
    </div>
  </div>
</div>

      <div id="zendesk-feedback-modal">
  <div class="modal-content zendesk-modal-content">
    <div class="modal-header">
      <button type="button" class="close" data-dismiss="modal" aria-label="Close">
        <span aria-hidden="true">×</span>
      </button>
      <h3>Website Feedback</h3>
    </div>

    <div class="modal-body">
      <form novalidate="novalidate" class="simple_form zendesk_ticket" enctype="multipart/form-data" action="/zendesk_tickets" accept-charset="UTF-8" method="post">
        <div class="form-group string required zendesk_ticket_name"><label class="control-label string required" for="zendesk_ticket_name"><abbr title="required">*</abbr> Your Name</label><input class="form-control string required" required="required" aria-required="true" type="text" name="zendesk_ticket[name]" id="zendesk_ticket_name" /></div>
        <div class="form-group email required zendesk_ticket_email"><label class="control-label email required" for="zendesk_ticket_email"><abbr title="required">*</abbr> Email</label><input class="form-control string email required" required="required" aria-required="true" type="email" name="zendesk_ticket[email]" id="zendesk_ticket_email" /></div>
        <div class="form-group file optional zendesk_ticket_attachment"><label class="control-label file optional" for="zendesk_ticket_attachment">Attachment</label><input class="file optional" type="file" name="zendesk_ticket[attachment]" id="zendesk_ticket_attachment" /></div>
        <div class="form-group text required zendesk_ticket_comment"><label class="control-label text required" for="zendesk_ticket_comment"><abbr title="required">*</abbr> How can we help you?</label><textarea class="form-control text required" name="zendesk_ticket[comment]" id="zendesk_ticket_comment">
</textarea></div>
        <div class="form-group boolean required zendesk_ticket_technical_help"><div class="checkbox"><input value="0" autocomplete="off" type="hidden" name="zendesk_ticket[technical_help]" /><label class="boolean required" for="zendesk_ticket_technical_help"><input class="boolean required" required="required" aria-required="true" type="checkbox" value="1" name="zendesk_ticket[technical_help]" id="zendesk_ticket_technical_help" /><abbr title="required">*</abbr> I am requesting technical help or providing website feedback</label></div></div>
          <div class="modal-text">
            This contact form is only for website help or website suggestions. If you have questions or comments regarding a published document please
            contact the publishing agency. Comments or questions about document content can not be answered by OFR staff. Please do not provide confidential
            information or personal data.
          </div>
        <div class="form-group text-left">
          <input type="submit" name="commit" value="Create Ticket" class="btn btn-primary btn-medium" data-disable-with="Create Ticket" />
        </div>
</form>    </div>
  </div>
</div>


    

    <div class="container">
      <div class='row'>
        <div class="col-xs-12 col-md-12 layout-header">
          <div class="main-navigation" id="main-navigation">
  <ul class="container">
    <li id='nav-home' class="nav-home" tabindex>
      <a class="home" aria-label="Home" href="/">
        <span class="icon-ecfr icon-ecfr-home "></span>
</a>    </li>

    <li id='nav-browse' class="dropdown nav-browse" tabindex=0>
      <a class="top-nav">
        <span class="icon-ecfr icon-ecfr-eye "></span>
        Browse
        <span class="icon-ecfr icon-ecfr-menu-arrow "></span>
      </a>

      <ul class="subnav dropdown-list">
        <li>
          <a href="/titles"><span class="icon-ecfr icon-ecfr-book "></span> Titles</a>
        </li>
        <li>
          <a href="/agencies"><span class="icon-ecfr icon-ecfr-mindmap "></span> Agencies</a>
        </li>
        <li>
          <a href="/incorporation-by-reference"><span class="icon-ecfr icon-ecfr-directions-alt "></span> Incorporation by Reference</a>
        </li>
        <li>
          <a href="/issues"><span class="icon-ecfr icon-ecfr-hourglass "></span> Recent Updates</a>
        </li>
      </ul>
    </li>

    <li id='nav-search' class="nav-search" tabindex>
      <a class="search" aria-label="eCFR Search" href="/search">
        <span class="icon-ecfr icon-ecfr-search "></span> Search
</a>    </li>

    <li id='nav-recent-changes' class="nav-recent-changes" tabindex>
      <a aria-label="eCFR Recent Changes" href="/recent-changes">
        <span class="icon-ecfr icon-ecfr-hourglass "></span> Recent Changes
</a>    </li>

    <li id='nav-ecfr-corrections' class="nav-recent-changes" tabindex>
      <a aria-label="eCFR Corrections" href="/corrections/2025">
        <span class="icon-ecfr icon-ecfr-merge "></span> Corrections
</a>    </li>

    <li id='nav-reader-aids' class="dropdown nav-reader-aids" tabindex=0>
      <a class="top-nav">
        <span class="icon-ecfr icon-ecfr-directions "></span>
        Reader Aids
        <span class="icon-ecfr icon-ecfr-menu-arrow "></span>
      </a>

      <ul class="subnav dropdown-list hierarchical" tabindex=0>
        <li>
          <a tabindex="0" href="/reader-aids">Reader Aids Home</a>
        </li>
          <li>
            <a tabindex="0" href="/reader-aids/using-ecfr">Using the eCFR Point-in-Time System</a>
          </li>
          <li>
            <a tabindex="0" href="/reader-aids/understanding-the-ecfr">Understanding the eCFR</a>
          </li>
          <li>
            <a tabindex="0" href="/reader-aids/government-policy-and-ofr-procedures">Government Policy and OFR Procedures</a>
          </li>
          <li>
            <a tabindex="0" href="/reader-aids/ecfr-developer-resources">Developer Resources</a>
          </li>
      </ul>
    </li>

    <li id='nav-my-ecfr' class="dropdown nav-my-ecfr" tabindex=0>
      <a class="top-nav">
        <span class="icon-ecfr icon-ecfr-male-female-user "></span>
        My eCFR
        <span class="icon-ecfr icon-ecfr-menu-arrow "></span>
      </a>

      <ul class="subnav dropdown-list signed-in hidden" tabindex=0>
        <li>
          <a href="/my/subscriptions">My Subscriptions</a>
        </li>
        <li>
          <a data-turbo="false" href="/sign_out">Sign Out</a>
        </li>
      </ul>

      <ul class="subnav dropdown-list signed-out" tabindex=0>
        <li>
          <a data-turbo="false" href="https://www.ecfr.gov/auth/sign_in?jwt=eyJhbGciOiJIUzI1NiJ9.eyJub3RpZmljYXRpb25zIjp7ImluZm8iOiJZb3Ugd2lsbCBiZSByZWRpcmVjdGVkIGJhY2sgdG8gdGhlIGVDRlIgYWZ0ZXIgeW91IGhhdmUgc2lnbmVkIGluIG9yIGNyZWF0ZWQgYW4gYWNjb3VudC4ifX0.-sYkHWfC02yb0CpuUqmPkxxnF0yzlNHaS5520hYIUy8&amp;redirect_to=https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50">Sign In / Sign Up</a>
        </li>
      </ul>
    </li>

    <li id='nav-inline-search' class="nav-inline-search" data-controller="placeholder">
      <form class="simple_form nav-search-form" novalidate="novalidate" action="/search" accept-charset="UTF-8" method="get">
        <input value="current" class="hidden" autocomplete="off" type="hidden" name="search[date]" id="search_date" />

          <input value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;A&quot;,&quot;part&quot;:&quot;50&quot;}" autocomplete="off" type="hidden" name="search[prior_hierarchy]" id="search_prior_hierarchy" />

        <input autocomplete="off" class="string required nav-search-query" data-action="click-&gt;placeholder#suggestions" placeholder="Search the eCFR" type="text" name="search[query]" id="search_query" />

        <button name="button" type="submit" class="nav-search-btn" title="Search" data-action="click-&gt;placeholder#suggestions">
          <span class="icon-ecfr icon-ecfr-search "></span>
</button>
        <div class='current-hierarchy-dropdown hidden'>
        </div>
</form>    </li>
  </ul>

  <div class='user-utils'>
    <div class='signed-out'>
      <a class="utils-signed-out" tabindex="-1" data-turbo="false" href="https://www.ecfr.gov/auth/sign_in?jwt=eyJhbGciOiJIUzI1NiJ9.eyJub3RpZmljYXRpb25zIjp7ImluZm8iOiJZb3Ugd2lsbCBiZSByZWRpcmVjdGVkIGJhY2sgdG8gdGhlIGVDRlIgYWZ0ZXIgeW91IGhhdmUgc2lnbmVkIGluIG9yIGNyZWF0ZWQgYW4gYWNjb3VudC4ifX0.-sYkHWfC02yb0CpuUqmPkxxnF0yzlNHaS5520hYIUy8&amp;redirect_to=https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50">Sign In / Sign Up</a>
    </div>

    <div class='signed-in hidden'>
      <p>
        Hi, <span class='user-email'></span>
          <a data-turbo="false" tabindex="-1" href="/sign_out">Sign Out</a>
      </p>
    </div>
  </div>
</div>


<div class="container">
  <div class="row">
    <div class="col-xs-12">
      <div class="logo">
        <div class="hgroup standard">
          <hgroup>
            <h1><a href="/" title="eCFR Home" tabindex=-1>eCFR</a></h1>
            <h2>The Electronic Code of Federal Regulations</h2>
          </hgroup>
        </div>
      </div>
    </div>
  </div>
</div>


        </div>
      </div>
    </div>

    <div class="container">
      <div class='external-url-modal'></div>
      <div class="modal fr-citation-modal" id="frCitationModal" tabindex="-1" role="dialog" aria-labelledby="Federal Register Citation Modal">
        <div class="modal-dialog" role="document">
          <div class="modal-content">
            <span class="icon-ecfr icon-ecfr-badge-x "></span>
            <div class="box box-enhanced "><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content :: FR Reference</h6><div class="row seal-meta"><div class="seal-desc col-md-12 col-xs-12"><p>Enhanced content is provided to the user to provide additional context.</p></div></div></div></div><div class="content-block ">
              <div class="modal-body"></div>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content :: FR Reference</h6></div></div>          </div>
        </div>
      </div>

      <div class='row'>
        <div class="col-xs-12 col-md-12 title-bar-col">
          <div id="page-top" class="main-title-bar "><div class="bar left"></div><h1 class="">  <span class="icon-ecfr icon-ecfr-books "></span>
  Title 21
</h1><div class="bar right"></div></div>
        </div>
      </div>


          <div class="row " >
  <div class="col-xs-12 col-md-12 content-notification basic print-only print-only-legal-notice"
    id="content-notification-f4223aa6"
  >
    <div class="">

      

      <div class="message">
        <p>This content is from the eCFR and is authoritative but unofficial.<p>
      </div>

    </div>
  </div>
</div>

  <div class="row " >
  <div class="col-xs-12 col-md-12 content-notification info"
    id="content-notification-a4841755"
  >
    <div class="">

      <span class="icon-ecfr icon-ecfr-calendar-alt "></span>

      <div class="message">
        Displaying title 21, up to date as of 4/10/2025. Title 21 was last amended 3/31/2025.<span class="reader-aid"><span data-toggle="tooltip" data-title="Click to learn more about dates in eCFR." class="svg-tooltip clickable" data-url="/reader-aids/understanding-the-ecfr/what-is-the-ecfr#special-rules-and-proceedures-for-future-amendments" data-container="span.reader-aid"><svg class="ecfr-svg-icon ecfr-svg-icon-info-circle "><use xlink:href="/assets/ecfr-icons-c08c495b1eda093da23b5b159c24927a91aa7c13df40f52ca7d30476904de0ea.svg#ecfr-svg-icon-info-circle"></use></svg></span></span>
      </div>

        <div class="message-link">
          <a class="msg-link message-go-to-version" href="#">view historical versions</a>
        </div>
    </div>
  </div>
</div>

  <div class="row hidden" >
  <div class="col-xs-12 col-md-12 content-notification danger"
    id="drafting-site-notification"
  >
    <div class="">
        <div class="dismiss-link">
          <span class="icon-ecfr icon-ecfr-badge-x "></span>
        </div>

      <span class="icon-ecfr icon-ecfr-alert-alt "></span>

      <div class="message">
        A <a data-drafting="true" href="https://drafting.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50">drafting site is available</a> for use when drafting amendatory language
      </div>

        <div class="message-link">
          <a data-drafting="true" class="msg-link" href="https://drafting.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50">switch to drafting site</a>
        </div>
    </div>
  </div>
</div>






      <div class='row'>
        <div class="col-xs-12 col-md-12 content-col">
          <div>
  <div id="suggestions" data-controller="suggestions autocomplete"
    data-autocomplete-url-value="/suggestions"
    data-autocomplete-delay-value="300">

    <div class="modal hidden" data-controller="modal"
      data-action="keyup@document->modal#escClose"
      data-suggestions-target="modal">

      <button class="backdrop" type="button" tabindex="-1"
        data-action="modal#close"></button>

      <div class="content">

        <div class="panel panel-default panel-info" data-suggestions-target="help">
          <div class="panel-heading">
            <p>
              <strong>Navigate by entering citations or phrases</strong>
              (eg:
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">1 CFR 1.1</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">49 CFR 172.101</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">Organization and Purpose</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">1/1.1</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">Regulation Y</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">FAR</span>).
            </p>
            <p>
              Choosing an item from
              <span class="suggestion-header-example">citations and headings</span>
              will bring you directly to the content. Choosing an item from
              <span class="suggestion-header-example">full text search results</span>
              will bring you to those results. Pressing enter in the search box
              will also bring you to search results.
            </p>
            <p>
              Background and more details are available in the
              <em>
                <a href="/reader-aids/using-ecfr/navigating-to-content-of-interest#search-navigation">Search &amp; Navigation</a>
              </em>
              guide.
            </p>
          </div>
        </div>

        <div class="cfr-ref-wrapper go-to-cfr-reference">
          <form class="simple_form go-to-cfr-reference" data-suggestions-target="form" data-turbo="false" novalidate="novalidate" action="/cfr-reference" accept-charset="UTF-8" method="get">
            <input value="current" data-param="date" autocomplete="off" type="hidden" name="search[date]" id="search_date" />
            <input value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;A&quot;,&quot;part&quot;:&quot;50&quot;}" data-param="hierarchy" autocomplete="off" type="hidden" name="search[hierarchy]" id="search_hierarchy" />
            <input value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;A&quot;,&quot;part&quot;:&quot;50&quot;}" data-param="prior_hierarchy" autocomplete="off" type="hidden" name="search[prior_hierarchy]" id="search_prior_hierarchy" />

            <div class="input-group input-group-lg">
              <input type="text" class="form-control"
                placeholder="Enter a search term or CFR reference (eg. fishing or 1 CFR 1.1)"
                aria-describedby="reference-search-icon"
                data-autocomplete-target="input"
                data-suggestions-target="input"
                name="search[query]"
                id="suggestion_query">

              <span class="input-group-btn"
                id="reference-search-icon"
                aria-label="search">
                <button class="btn btn-optional" type="button"
                  data-suggestions-target="searchIcon"
                  data-action="click->suggestions#goDefault">
                    <span class="icon-ecfr icon-ecfr-search "></span>
                </button>
              </span>
            </div>

            <div data-autocomplete-target="results"
              data-suggestions-target="results"></div>
</form>        </div>

      </div>
    </div>

    <form class="simple_form go-to-cfr-reference hidden" data-suggestions-target="nonModalForm" novalidate="novalidate" action="/cfr-reference" accept-charset="UTF-8" method="get">
      <input label="false" value="current" autocomplete="off" type="hidden" name="cfr[date]" id="cfr_date" />
      <input value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;A&quot;,&quot;part&quot;:&quot;50&quot;}" autocomplete="off" type="hidden" name="cfr[prior_hierarchy]" id="cfr_prior_hierarchy" />
      <input data-autocomplete-target="hidden" autocomplete="off" type="hidden" name="cfr[suggestion_id]" id="cfr_suggestion_id" />

      <div class="input-group input-group-lg">
        <input type="text" class="form-control string optional"
          data-action="focus->suggestions#modal"
          placeholder="Enter a search term or CFR reference (eg. fishing or 1 CFR 1.1)"
          type="text"
          data-suggestions-target="nonModalInput"
          name="cfr[reference]"
          id="suggestion">
        <span class="input-group-btn"
          data-action="click->suggestions#go">

          <button class="btn btn-optional" type="button"
            data-suggestions-target="nonModalSearchIcon"
            data-action="click->suggestions#go">
              <span class="icon-ecfr icon-ecfr-search "></span>
          </button>
        </span>
      </div>
</form>  </div>
</div>

          



<div class='row'>
  <div class="col-xs-12 col-md-12 no-padding">
    <div class='cfr-ref-wrapper'>
  <div data-controller="placeholder">
    <form class="simple_form go-to-cfr-reference" novalidate="novalidate" action="/cfr-reference" accept-charset="UTF-8" method="get">

      <div class="input-group input-group-lg">
        <input type="text" class="form-control string optional"
          data-action="focus->placeholder#suggestions"
          placeholder="Enter a search term or CFR reference (eg. fishing or 1 CFR 1.1)"
          type="text"
          data-suggestions-target="nonModalInput"
          name="cfr[reference]"
          id="suggestion">
        <span class="input-group-btn"
          data-action="click->placeholder#suggestions">

          <button class="btn btn-optional" type="button"
            data-suggestions-target="nonModalSearchIcon"
            data-action="click->placeholder#suggestions">
              <span class="icon-ecfr icon-ecfr-search "></span>
          </button>
        </span>
      </div>
</form>  </div>
</div>

  </div>
</div>

<div class="row breadcrumbs-wrapper ">
  <div class="col-xs-12 col-md-12 breadcrumb-nav" data-hierarchy="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;A&quot;,&quot;part&quot;:&quot;50&quot;}" data-filtered-search-enabled="true">
    <div class='row'>
      <div class="col-xs-12 col-md-9">
        <ol>
    <li class="">
        <a class="breadcrumb-link" data-toggle="tooltip" data-placement="top" data-title="View Table of Contents for Title 21—Food and Drugs" href="/current/title-21">Title 21 <span class="print-only breadcrumbs-title" data-hierarchy="{'title':'21'}">—Food and Drugs</span></a>
    </li>
    <li class="">
        <a class="breadcrumb-link" data-toggle="tooltip" data-placement="top" data-title="View Table of Contents for  Chapter I—Food and Drug Administration, Department of Health and Human Services" href="/current/title-21/chapter-I"> Chapter I <span class="print-only breadcrumbs-title" data-hierarchy="{'title':'21','chapter':'I'}">—Food and Drug Administration, Department of Health and Human Services</span></a>
    </li>
    <li class="">
        <a class="breadcrumb-link" data-toggle="tooltip" data-placement="top" data-title="View Table of Contents for Subchapter A—General" href="/current/title-21/chapter-I/subchapter-A">Subchapter A <span class="print-only breadcrumbs-title" data-hierarchy="{'title':'21','chapter':'I','subchapter':'A'}">—General</span></a>
    </li>
    <li class="breadcrumb-current">
        Part 50

    </li>
</ol>

      </div>

      <div class="col-xs-12 col-md-3 text-right">
        <ul class="prev-next-breadcrumb-nav">
  <li>
      <a id="previous-content-link" data-title="Part 26—Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and the European Community" data-html="true" href="/current/title-21/chapter-I/subchapter-A/part-26">Previous</a>
  </li>

  <li>
      <a id="next-content-link" data-title="Part 54—Financial Disclosure by Clinical Investigators" data-html="true" href="/current/title-21/chapter-I/subchapter-A/part-54">Next</a>
  </li>

  <li id="breadcrumb-back-to-top">
    <a data-title="Back to Top" data-turbo="false" href="#page-top">Top</a>
  </li>
</ul>

      </div>
    </div>
</div></div>


<div class="row ecfr-content-wrapper">
  <div class="col-xs-12 col-md-12 ecfr-content with-utility-bar">
    <div class="row">
      <div class="col-xs-3 col-sm-2 content-nav-wrapper content-nav-wrapper-wide">
        
<ul class="content-nav text-center dropdown drop-enhanced ui sticky">
  <li class="button">
    <span role="button" arial-label="compress content nav" class="icon-ecfr icon-ecfr-previous-media content-nav-compress-toggle"></span>
  </li>

  

<li class="enhanced " id="utility-nav-toc" tabindex="0"><span role="button" aria-label="Table of Contents" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Table of Contents" class="icon-ecfr icon-ecfr-book "></span><span class="content-nav-label " role="button">Table of Contents</span><div class="box box-enhanced box-enhanced-toc box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Table of Contents</h6></div></div><div class="content-block ">      <table class="table-of-contents root">
        <tr class="part  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Part 50&lt;/span&gt;">Part 50</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Part 50&lt;/span&gt;"><a data-turbo="false" href="#part-50">Protection of Human Subjects</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Part 50&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;50.1 – 50.56&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-A/part-50?toc=1">50.1 – 50.56</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="subpart  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart A&lt;/span&gt;">Subpart A</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart A&lt;/span&gt;"><a data-turbo="false" href="#subpart-A">General Provisions</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart A&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;50.1 – 50.3&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-A/part-50/subpart-A?toc=1">50.1 – 50.3</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.1&lt;/span&gt;">§ 50.1</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.1&lt;/span&gt;"><a data-turbo="false" href="#50.1">Scope.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.3&lt;/span&gt;">§ 50.3</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.3&lt;/span&gt;"><a data-turbo="false" href="#50.3">Definitions.</a></span></td></tr></table></td></tr><tr class="subpart  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart B&lt;/span&gt;">Subpart B</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart B&lt;/span&gt;"><a data-turbo="false" href="#subpart-B">Informed Consent of Human Subjects</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart B&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;50.20 – 50.27&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-A/part-50/subpart-B?toc=1">50.20 – 50.27</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.20&lt;/span&gt;">§ 50.20</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.20&lt;/span&gt;"><a data-turbo="false" href="#50.20">General requirements for informed consent.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.22&lt;/span&gt;">§ 50.22</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.22&lt;/span&gt;"><a data-turbo="false" href="#50.22">Exception from informed consent requirements for minimal risk clinical investigations.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.23&lt;/span&gt;">§ 50.23</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.23&lt;/span&gt;"><a data-turbo="false" href="#50.23">Exception from general requirements.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.24&lt;/span&gt;">§ 50.24</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.24&lt;/span&gt;"><a data-turbo="false" href="#50.24">Exception from informed consent requirements for emergency research.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.25&lt;/span&gt;">§ 50.25</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.25&lt;/span&gt;"><a data-turbo="false" href="#50.25">Elements of informed consent.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.27&lt;/span&gt;">§ 50.27</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.27&lt;/span&gt;"><a data-turbo="false" href="#50.27">Documentation of informed consent.</a></span></td></tr></table></td></tr><tr class="reserved subpart toc-leaf-node "><td colspan="3"><span class="description">Subpart C [Reserved]</span></td></tr><tr class="subpart  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart D&lt;/span&gt;">Subpart D</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart D&lt;/span&gt;"><a data-turbo="false" href="#subpart-D">Additional Safeguards for Children in Clinical Investigations</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart D&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;50.50 – 50.56&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-A/part-50/subpart-D?toc=1">50.50 – 50.56</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.50&lt;/span&gt;">§ 50.50</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.50&lt;/span&gt;"><a data-turbo="false" href="#50.50">IRB duties.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.51&lt;/span&gt;">§ 50.51</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.51&lt;/span&gt;"><a data-turbo="false" href="#50.51">Clinical investigations not involving greater than minimal risk.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.52&lt;/span&gt;">§ 50.52</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.52&lt;/span&gt;"><a data-turbo="false" href="#50.52">Clinical investigations involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.53&lt;/span&gt;">§ 50.53</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.53&lt;/span&gt;"><a data-turbo="false" href="#50.53">Clinical investigations involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subjects' disorder or condition.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.54&lt;/span&gt;">§ 50.54</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.54&lt;/span&gt;"><a data-turbo="false" href="#50.54">Clinical investigations not otherwise approvable that present an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.55&lt;/span&gt;">§ 50.55</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.55&lt;/span&gt;"><a data-turbo="false" href="#50.55">Requirements for permission by parents or guardians and for assent by children.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.56&lt;/span&gt;">§ 50.56</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 50.56&lt;/span&gt;"><a data-turbo="false" href="#50.56">Wards.</a></span></td></tr></table></td></tr></table></td></tr>
      </table>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Table of Contents</h6></div></div></li>

  
<li class="enhanced " id="utility-nav-details" tabindex="0"><span role="button" aria-label="Details" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Details" class="icon-ecfr icon-ecfr-book-alt-2 "></span><span class="content-nav-label " role="button">Details</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Details</h6></div></div><div class="content-block ">    <dl class="">
      <dt>URL</dt>
      <dd>
        https://www.ecfr.gov/current/title-21/part-50
        <span data-toggle="tooltip" data-title="Copy to Clipboard" class="svg-tooltip copy-to-clipboard" data-title-copied="Copied to Clipboard" data-copy-text="https://www.ecfr.gov/current/title-21/part-50"><svg class="ecfr-svg-icon ecfr-svg-icon-content-copy "><use xlink:href="/assets/ecfr-icons-c08c495b1eda093da23b5b159c24927a91aa7c13df40f52ca7d30476904de0ea.svg#ecfr-svg-icon-content-copy"></use></svg></span>
      </dd>

        <dt>Citation</dt>
        <dd>
          21 CFR Part 50
          <span data-toggle="tooltip" data-title="Copy to Clipboard" class="svg-tooltip copy-to-clipboard" data-title-copied="Copied to Clipboard" data-copy-text="21 CFR Part 50"><svg class="ecfr-svg-icon ecfr-svg-icon-content-copy "><use xlink:href="/assets/ecfr-icons-c08c495b1eda093da23b5b159c24927a91aa7c13df40f52ca7d30476904de0ea.svg#ecfr-svg-icon-content-copy"></use></svg></span>
        </dd>



        <dt>
          Agency
          <span data-toggle="tooltip" data-title="The agency currently associated with this eCFR content. Click for more details." class="svg-tooltip clickable" data-url="/reader-aids/using-ecfr/agency-references#details_sidebar" data-container="dl"><svg class="ecfr-svg-icon ecfr-svg-icon-info-circle "><use xlink:href="/assets/ecfr-icons-c08c495b1eda093da23b5b159c24927a91aa7c13df40f52ca7d30476904de0ea.svg#ecfr-svg-icon-info-circle"></use></svg></span>
        </dt>
          <dd data-issuing-agency=food-and-drug-administration>Food and Drug Administration, Department of Health and Human Services</dd>
    </dl>

    <hr>

    <div id="source-and-authority">
        <div class="additional-source-and-authority">
      <div class="level">
        <a href="/current/title-21/part-50" class="cfr reference">Part 50</a>
        <div class="details" data-hierarchy="{:title=&gt;&quot;21&quot;, :chapter=&gt;&quot;I&quot;, :subchapter=&gt;&quot;A&quot;, :part=&gt;&quot;50&quot;}" data-current="true">
            <div class="authority">
              <h4 class="inline-header">Authority:</h4>
              <p class="inline-paragraph">
                <a href="https://www.govinfo.gov/link/uscode/21/321" class="usc external" target="_blank" rel="noopener noreferrer">21 U.S.C. 321</a>, <a href="https://www.govinfo.gov/link/uscode/21/343" class="usc external" target="_blank" rel="noopener noreferrer">343</a>, <a href="https://www.govinfo.gov/link/uscode/21/346" class="usc external" target="_blank" rel="noopener noreferrer">346</a>, <a href="https://www.govinfo.gov/link/uscode/21/346a" class="usc external" target="_blank" rel="noopener noreferrer">346a</a>, <a href="https://www.govinfo.gov/link/uscode/21/348" class="usc external" target="_blank" rel="noopener noreferrer">348</a>, <a href="https://www.govinfo.gov/link/uscode/21/350a" class="usc external" target="_blank" rel="noopener noreferrer">350a</a>, <a href="https://www.govinfo.gov/link/uscode/21/350b" class="usc external" target="_blank" rel="noopener noreferrer">350b</a>, <a href="https://www.govinfo.gov/link/uscode/21/352" class="usc external" target="_blank" rel="noopener noreferrer">352</a>, <a href="https://www.govinfo.gov/link/uscode/21/353" class="usc external" target="_blank" rel="noopener noreferrer">353</a>, <a href="https://www.govinfo.gov/link/uscode/21/355" class="usc external" target="_blank" rel="noopener noreferrer">355</a>, <a href="https://www.govinfo.gov/link/uscode/21/360" class="usc external" target="_blank" rel="noopener noreferrer">360</a>, <a href="https://www.govinfo.gov/link/uscode/21/360c" class="usc external" target="_blank" rel="noopener noreferrer">360c-360f</a>, <a href="https://www.govinfo.gov/link/uscode/21/360h" class="usc external" target="_blank" rel="noopener noreferrer">360h-360j</a>, <a href="https://www.govinfo.gov/link/uscode/21/371" class="usc external" target="_blank" rel="noopener noreferrer">371</a>, <a href="https://www.govinfo.gov/link/uscode/21/379e" class="usc external" target="_blank" rel="noopener noreferrer">379e</a>, <a href="https://www.govinfo.gov/link/uscode/21/381" class="usc external" target="_blank" rel="noopener noreferrer">381</a>; <a href="https://www.govinfo.gov/link/uscode/42/216" class="usc external" target="_blank" rel="noopener noreferrer">42 U.S.C. 216</a>, <a href="https://www.govinfo.gov/link/uscode/42/241" class="usc external" target="_blank" rel="noopener noreferrer">241</a>, <a href="https://www.govinfo.gov/link/uscode/42/262" class="usc external" target="_blank" rel="noopener noreferrer">262</a>.


              </p>
            </div>
            <div class="source">
              <h4 class="inline-header">Source:</h4>
              <p class="inline-paragraph">
                <a href="https://www.federalregister.gov/citation/45-FR-36390" class="fr-reference" data-reference="45 FR 36390">45 FR 36390</a>, May 30, 1980, unless otherwise noted.


              </p>
            </div>
        </div>
      </div>
  </div>

    </div>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Details</h6></div></div></li>

  
<li class="enhanced " id="" tabindex="0"><span role="button" aria-label="Print/PDF" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Print/PDF" class="icon-ecfr icon-ecfr-print "></span><span class="content-nav-label " role="button">Print/PDF</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Print</h6></div></div><div class="content-block ">      <p>
        <a class="generate-pdf" data-original-text="Generate PDF <small class=&quot;text-warning&quot;>(approximately 10+ pages)</small>" href="#">Generate PDF <small class="text-warning">(approximately 10+ pages)</small></a>

        <span class="pdf-spinner" style="display:none;">
          <span class="spinner"></span>
        </span>
      </p>
      <p>
        This content is from the eCFR and may include recent changes applied to the CFR.
        The official, published CFR, is updated annually and available below under
        "Published Edition". You can learn more about the process
        <a href="https://www.govinfo.gov/help/cfr#about">here</a>.
      </p>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Print</h6></div></div></li>

  
<li class="enhanced " id="" tabindex="0"><span role="button" aria-label="Display Options" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Display Options" class="icon-ecfr icon-ecfr-doc-generic "></span><span class="content-nav-label " role="button">Display Options</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Display Options</h6></div></div><div class="content-block ">    <turbo-frame id="side_display" src="/display/current/title-21/chapter-I/subchapter-A/part-50" loading="lazy">
      <span class="timeline-spinner">
        <span class="spinner"></span>
      </span>
    </turbo-frame>  
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Display Options</h6></div></div></li>

  
<li class="enhanced utility-nav-subscribe" id="utility-nav-subscribe" tabindex="0"><span role="button" aria-label="Subscribe" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Subscribe" class="icon-ecfr icon-ecfr-message "></span><span class="content-nav-label " role="button">Subscribe</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Subscribe</h6></div></div><div class="content-block ">    <p><strong>Subscribe to:</strong> 21 CFR Part 50</p>

    <div class="subscription-option">
      <form class="simple_form form-horizontal subscribe" id="new_subscription" data-turbo="false" novalidate="novalidate" action="/my/subscriptions" accept-charset="UTF-8" method="post">
            <div class="form-group hidden subscription_title"><input class="form-control hidden hierarchy-input" value="21" name="search[hierarchy][title]" autocomplete="off" type="hidden" id="subscription_title" /></div>
            <div class="form-group hidden subscription_chapter"><input class="form-control hidden hierarchy-input" value="I" name="search[hierarchy][chapter]" autocomplete="off" type="hidden" id="subscription_chapter" /></div>
            <div class="form-group hidden subscription_subchapter"><input class="form-control hidden hierarchy-input" value="A" name="search[hierarchy][subchapter]" autocomplete="off" type="hidden" id="subscription_subchapter" /></div>
            <div class="form-group hidden subscription_part"><input class="form-control hidden hierarchy-input" value="50" name="search[hierarchy][part]" autocomplete="off" type="hidden" id="subscription_part" /></div>

        <div class="subscription-option">
          <span class="icon-ecfr icon-ecfr-message "></span><label class='email-label'>Via Email:</label>
          <input type="submit" name="commit" value="Subscribe" class="btn-as-link" data-disable-with="Subscribe" />
        </div>

        <!-- <div class="subscription-option"> -->
          <!-- <label class='rss-label'>Via RSS:</label> -->

        <!-- </div> -->
</form>    </div>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Subscribe</h6></div></div></li>

  <li class="divider"></li>

    
<li class="enhanced " id="utility-nav-timeline" tabindex="0"><span role="button" aria-label="Timeline" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Timeline" class="icon-ecfr icon-ecfr-hourglass "></span><span class="content-nav-label " role="button">Timeline</span><div class="box box-enhanced box-enhanced-timeline box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Timeline</h6></div></div><div class="content-block ">
        <turbo-frame data-controller="timeline" id="side_timeline" target="_top">
      <ol class="timeline list with-bullets enhanced">
          <li>
            <span class='date current-change'>
              1/22/2024
            </span>

            <span class='timeline'>
              <a href="/on/2024-01-22/title-21/chapter-I/subchapter-A/part-50">view on this date</a>
            </span>

            <span class='timeline'>
              <a data-diff-path="/compare/2024-01-22/to/2024-01-21/title-21/chapter-I/subchapter-A/part-50" href="#">view change <span class="hidden-xs hidden-sm">introduced</span></a>
            </span>

              <span class='timeline'>&nbsp;</span>
          </li>
          <li>
            <span class='date'>
              12/21/2023
            </span>

            <span class='timeline'>
              <a href="/on/2023-12-21/title-21/chapter-I/subchapter-A/part-50">view on this date</a>
            </span>

            <span class='timeline'>
              <a data-diff-path="/compare/2023-12-21/to/2023-12-20/title-21/chapter-I/subchapter-A/part-50" href="#">view change <span class="hidden-xs hidden-sm">introduced</span></a>
            </span>

              <span class='timeline'><a data-diff-path="/compare/current/to/2023-12-21/title-21/chapter-I/subchapter-A/part-50" href="#">compare to most recent</a></span>
          </li>
      </ol>
</turbo-frame>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Timeline</h6></div></div></li>

  
<li class="enhanced " id="utility-nav-go-to-date" tabindex="0"><span role="button" aria-label="Go to Date" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Go to Date" class="icon-ecfr icon-ecfr-calendar-alt "></span><span class="content-nav-label " role="button">Go to Date</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Go to Date</h6></div></div><div class="content-block ">    <form class="simple_form form-horizontal go-to-date" id="go-to-date-form" autocomplete="off" novalidate="novalidate" action="#" accept-charset="UTF-8" method="get">

      <div class="form-group bootstrap_datepicker optional go_to_date_date"><label class="control-label bootstrap_datepicker optional" for="go_to_date_date">Date</label><div class='input-group'>
<input class="form-control bootstrap_datepicker optional bootstrap-datepicker" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" type="text" name="go_to_date[date_box]" id="go_to_date_date_box" />
<span class='input-group-addon calendar-btn'><span class='glyphicon glyphicon-calendar'></span></span>
</div>
<input class="form-control bootstrap_datepicker optional" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" id="date_hidden" value="" autocomplete="off" type="hidden" name="go_to_date[date]" />
</div>

      <input type="submit" name="commit" value="Go to date" class="btn btn-default btn btn-primary-alt btn-medium" data-disable-with="Go to date" />
</form>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Go to Date</h6></div></div></li>

  

<li class="enhanced " id="utility-nav-compare" tabindex="0"><span role="button" aria-label="Compare Dates" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Compare Dates" class="icon-ecfr icon-ecfr-forking "></span><span class="content-nav-label " role="button">Compare Dates</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Compare Dates</h6></div></div><div class="content-block ">      <form class="simple_form form-horizontal compare-content" id="new_compare" autocomplete="off" novalidate="novalidate" action="/compare" accept-charset="UTF-8" method="post">

        <div class="form-group bootstrap_datepicker optional compare_from"><label class="control-label bootstrap_datepicker optional" for="compare_from">Compare</label><div class='input-group'>
<input class="form-control bootstrap_datepicker optional bootstrap-datepicker" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" type="text" name="compare[from_box]" id="compare_from_box" />
<span class='input-group-addon calendar-btn'><span class='glyphicon glyphicon-calendar'></span></span>
</div>
<input class="form-control bootstrap_datepicker optional" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" id="from_hidden" value="" autocomplete="off" type="hidden" name="compare[from]" />
</div>

        <div class="form-group bootstrap_datepicker optional compare_to"><label class="control-label bootstrap_datepicker optional" for="compare_to">to</label><div class='input-group'>
<input class="form-control bootstrap_datepicker optional bootstrap-datepicker" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" type="text" value="04/09/2025" name="compare[to_box]" id="compare_to_box" />
<span class='input-group-addon calendar-btn'><span class='glyphicon glyphicon-calendar'></span></span>
</div>
<input class="form-control bootstrap_datepicker optional" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" id="to_hidden" value="2025-04-09" autocomplete="off" type="hidden" name="compare[to]" />
</div>

        <div class="form-group hidden compare_hierarchy"><input class="form-control hidden" autocomplete="off" type="hidden" value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;A&quot;,&quot;part&quot;:&quot;50&quot;,&quot;complete&quot;:true}" name="compare[hierarchy]" id="compare_hierarchy" /></div>
        <div class="form-group hidden compare_view_mode"><input class="form-control hidden" autocomplete="off" type="hidden" name="compare[view_mode]" id="compare_view_mode" /></div>

        <input type="submit" name="commit" value="Compare Dates" class="btn btn-default btn btn-primary-alt btn-medium" data-disable-with="Compare Dates" />
</form>
      <form class="simple_form compare-style-choices" id="new_compare_style_choices" novalidate="novalidate" action="#" accept-charset="UTF-8" method="get">
        <div class="form-group radio_buttons optional compare_style_choices_diff_color"><label class="control-label radio_buttons optional">Show changes as:</label><span class="radio"><label for="compare_style_choices_diff_color_rg-diff"><input class="radio_buttons optional" type="radio" value="rg-diff" checked="checked" name="compare_style_choices[diff_color]" id="compare_style_choices_diff_color_rg-diff" />red/green</label></span><span class="radio"><label for="compare_style_choices_diff_color_po-diff"><input class="radio_buttons optional" type="radio" value="po-diff" name="compare_style_choices[diff_color]" id="compare_style_choices_diff_color_po-diff" />purple/orange</label></span></div>

        <div class="form-group radio_buttons optional compare_style_choices_strikethrough"><label class="control-label radio_buttons optional">Show strike-through for removed content</label><span class="radio"><label for="compare_style_choices_strikethrough_true"><input class="radio_buttons optional" type="radio" value="true" checked="checked" name="compare_style_choices[strikethrough]" id="compare_style_choices_strikethrough_true" />yes</label></span><span class="radio"><label for="compare_style_choices_strikethrough_false"><input class="radio_buttons optional" readonly="readonly" type="radio" value="false" name="compare_style_choices[strikethrough]" id="compare_style_choices_strikethrough_false" />no</label></span></div>
</form></div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Compare Dates</h6></div></div></li>

  <li class="divider"></li>

  
<li class="enhanced published-edition" id="" tabindex="0"><span role="button" aria-label="Published Edition" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Published Edition" class="icon-ecfr icon-ecfr-doc-pdf "></span><span class="content-nav-label " role="button">Published Edition</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Published Edition</h6></div></div><div class="content-block ">    <p>
      View the most recent official publication:
    </p>

    <ul class="list with-bullets enhanced">
        <li>
          <a data-turbo="false" href="https://www.govinfo.gov/app/collection/cfr/2025">View Title 21 on govinfo.gov</a>
        </li>
        <li>
          <a data-turbo="false" href="https://www.govinfo.gov/link/cfr/21/50?link-type=pdf&amp;year=mostrecent">View the PDF for 21 CFR Part 50</a>
        </li>
    </ul>

    <p>
      These links go to the official, published CFR, which is updated annually. As a
      result, it may not include the most recent changes applied to the CFR.
      <a href="https://www.govinfo.gov/help/cfr#about">Learn more</a>.
    </p>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Published Edition</h6></div></div></li>

  <li class="divider"></li>

  
<li class="enhanced developer-tools" id="" tabindex="0"><span role="button" aria-label="Developer Tools" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Developer Tools" class="icon-ecfr icon-ecfr-console "></span><span class="content-nav-label " role="button">Developer Tools</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Developer Tools</h6></div></div><div class="content-block ">
      <turbo-frame id="side_developer" src="/developer/current/title-21/chapter-I/subchapter-A/part-50" loading="lazy">
        <span class="timeline-spinner">
          <span class="spinner"></span>
        </span>
        <br/><br/>
      </turbo-frame>

    <p>
      Information and documentation can be found in our
      <a href="/reader-aids/ecfr-developer-resources">developer resources</a>.
    </p>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Developer Tools</h6></div></div></li>
</ul>

      </div>

      <div class="col-xs-9 col-sm-10 content-col">
        <div class="box box-published no-print-header compare-settings"><div class="seal-block seal-block-header"><div class="seal-content"><h6>eCFR Content</h6><div class="row seal-meta"><div class="seal-desc col-md-12 col-xs-12"><p><p>The <em>Code of Federal Regulations</em> (CFR) is the official legal print publication containing the codification of the general and permanent rules published in the <em>Federal Register</em> by the departments and agencies of the Federal Government. The Electronic Code of Federal Regulations (eCFR) is a continuously updated online version of the CFR. It is not an official legal edition of the CFR.</p> <p><a href='/reader-aids/understanding-the-ecfr/what-is-the-ecfr'>Learn more</a> about the eCFR, its status, and the editorial process.<p></p></div></div></div></div><div class="content-block ">
            <div class="box box-enhanced slim toc-link no-footer"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content</h6></div></div><div class="content-block ">
              <span class="icon-ecfr icon-ecfr-book "></span> View
              <a id="toc-utility-nav-link" href="">table of contents</a>
              for this page.
</div><div class="seal-block seal-block-footer"></div></div>
          
<div class="part" id="part-50"><h1 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-50&quot;,&quot;citation&quot;:&quot;21 CFR Part 50&quot;}">PART 50—PROTECTION OF HUMAN SUBJECTS
</h1>

<div class="authority"><h4 class="inline-header">Authority:</h4><p class="inline-paragraph"><a href="https://www.govinfo.gov/link/uscode/21/321" class="usc external" target="_blank" rel="noopener noreferrer">21 U.S.C. 321</a>, <a href="https://www.govinfo.gov/link/uscode/21/343" class="usc external" target="_blank" rel="noopener noreferrer">343</a>, <a href="https://www.govinfo.gov/link/uscode/21/346" class="usc external" target="_blank" rel="noopener noreferrer">346</a>, <a href="https://www.govinfo.gov/link/uscode/21/346a" class="usc external" target="_blank" rel="noopener noreferrer">346a</a>, <a href="https://www.govinfo.gov/link/uscode/21/348" class="usc external" target="_blank" rel="noopener noreferrer">348</a>, <a href="https://www.govinfo.gov/link/uscode/21/350a" class="usc external" target="_blank" rel="noopener noreferrer">350a</a>, <a href="https://www.govinfo.gov/link/uscode/21/350b" class="usc external" target="_blank" rel="noopener noreferrer">350b</a>, <a href="https://www.govinfo.gov/link/uscode/21/352" class="usc external" target="_blank" rel="noopener noreferrer">352</a>, <a href="https://www.govinfo.gov/link/uscode/21/353" class="usc external" target="_blank" rel="noopener noreferrer">353</a>, <a href="https://www.govinfo.gov/link/uscode/21/355" class="usc external" target="_blank" rel="noopener noreferrer">355</a>, <a href="https://www.govinfo.gov/link/uscode/21/360" class="usc external" target="_blank" rel="noopener noreferrer">360</a>, <a href="https://www.govinfo.gov/link/uscode/21/360c" class="usc external" target="_blank" rel="noopener noreferrer">360c-360f</a>, <a href="https://www.govinfo.gov/link/uscode/21/360h" class="usc external" target="_blank" rel="noopener noreferrer">360h-360j</a>, <a href="https://www.govinfo.gov/link/uscode/21/371" class="usc external" target="_blank" rel="noopener noreferrer">371</a>, <a href="https://www.govinfo.gov/link/uscode/21/379e" class="usc external" target="_blank" rel="noopener noreferrer">379e</a>, <a href="https://www.govinfo.gov/link/uscode/21/381" class="usc external" target="_blank" rel="noopener noreferrer">381</a>; <a href="https://www.govinfo.gov/link/uscode/42/216" class="usc external" target="_blank" rel="noopener noreferrer">42 U.S.C. 216</a>, <a href="https://www.govinfo.gov/link/uscode/42/241" class="usc external" target="_blank" rel="noopener noreferrer">241</a>, <a href="https://www.govinfo.gov/link/uscode/42/262" class="usc external" target="_blank" rel="noopener noreferrer">262</a>.
</p></div>

<div class="source"><h4 class="inline-header">Source:</h4><p class="inline-paragraph"><a href="https://www.federalregister.gov/citation/45-FR-36390" class="fr-reference" data-reference="45 FR 36390">45 FR 36390</a>, May 30, 1980, unless otherwise noted.
</p></div>

<div class="subpart" id="subpart-A"><h2 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-50/subpart-A&quot;,&quot;citation&quot;:&quot;21 CFR Part 50 Subpart A&quot;}">Subpart A—General Provisions</h2>
<div class="section" id="50.1">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.1","citation":"21 CFR 50.1"}'>§ 50.1 Scope.</h4>
<div id="p-50.1(a)">
<p class="indent-1" data-title="50.1(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> This part applies to all clinical investigations regulated by the Food and Drug Administration under sections 505(i) and 520(g) of the Federal Food, Drug, and Cosmetic Act, as well as clinical investigations that support applications for research or marketing permits for products regulated by the Food and Drug Administration, including foods, including dietary supplements, that bear a nutrient content claim or a health claim, infant formulas, food and color additives, drugs for human use, medical devices for human use, biological products for human use, and electronic products. Additional specific obligations and commitments of, and standards of conduct for, persons who sponsor or monitor clinical investigations involving particular test articles may also be found in other parts (e.g., parts 312 and 812). Compliance with these parts is intended to protect the rights and safety of subjects involved in investigations filed with the Food and Drug Administration pursuant to sections 403, 406, 409, 412, 413, 502, 503, 505, 510, 513-516, 518-520, 721, and 801 of the Federal Food, Drug, and Cosmetic Act and sections 351 and 354-360F of the Public Health Service Act.</p>
</div>
<div id="p-50.1(b)"><p class="indent-1" data-title="50.1(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/45-FR-36390" class="fr-reference" data-reference="45 FR 36390">45 FR 36390</a>, May 30, 1980; <a href="https://www.federalregister.gov/citation/46-FR-8979" class="fr-reference" data-reference="46 FR 8979">46 FR 8979</a>, Jan. 27, 1981, as amended at <a href="https://www.federalregister.gov/citation/63-FR-26697" class="fr-reference" data-reference="63 FR 26697">63 FR 26697</a>, May 13, 1998; <a href="https://www.federalregister.gov/citation/64-FR-399" class="fr-reference" data-reference="64 FR 399">64 FR 399</a>, Jan. 5, 1999; <a href="https://www.federalregister.gov/citation/66-FR-20597" class="fr-reference" data-reference="66 FR 20597">66 FR 20597</a>, Apr. 24, 2001]
</p>
</div>

<div class="section" id="50.3">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.3","citation":"21 CFR 50.3"}'>§ 50.3 Definitions.</h4>
<p>As used in this part:</p>
<div id="p-50.3(a)">
<p class="indent-1" data-title="50.3(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Act</em>  means the Federal Food, Drug, and Cosmetic Act, as amended (secs. 201-902, 52 Stat. 1040 <em>et seq.</em> as amended (<a href="https://www.govinfo.gov/link/uscode/21/321" class="usc external" target="_blank" rel="noopener noreferrer">21 U.S.C. 321-392</a>)).</p>
</div>
<div id="p-50.3(b)">
<p class="indent-1" data-title="50.3(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Application for research or marketing permit</em>  includes:</p>
<div id="p-50.3(b)(1)">
<p class="indent-2" data-title="50.3(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> A color additive petition, described in part 71.</p>
</div>
<div id="p-50.3(b)(2)">
<p class="indent-2" data-title="50.3(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> A food additive petition, described in parts 171 and 571.</p>
</div>
<div id="p-50.3(b)(3)">
<p class="indent-2" data-title="50.3(b)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> Data and information about a substance submitted as part of the procedures for establishing that the substance is generally recognized as safe for use that results or may reasonably be expected to result, directly or indirectly, in its becoming a component or otherwise affecting the characteristics of any food, described in <a href="/current/title-21/section-170.30" class="cfr external">§§ 170.30</a> and <a href="/current/title-21/section-570.30" class="cfr external">570.30</a>.</p>
</div>
<div id="p-50.3(b)(4)">
<p class="indent-2" data-title="50.3(b)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> Data and information about a food additive submitted as part of the procedures for food additives permitted to be used on an interim basis pending additional study, described in <a href="/current/title-21/section-180.1" class="cfr external">§ 180.1</a>.</p>
</div>
<div id="p-50.3(b)(5)">
<p class="indent-2" data-title="50.3(b)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> Data and information about a substance submitted as part of the procedures for establishing a tolerance for unavoidable contaminants in food and food-packaging materials, described in section 406 of the act.</p>
</div>
<div id="p-50.3(b)(6)">
<p class="indent-2" data-title="50.3(b)(6)"><span class="paragraph-hierarchy"><span class="paren">(</span>6<span class="paren">)</span></span> An investigational new drug application, described in <a href="/current/title-21/part-312" class="cfr external">part 312 of this chapter</a>.</p>
</div>
<div id="p-50.3(b)(7)">
<p class="indent-2" data-title="50.3(b)(7)"><span class="paragraph-hierarchy"><span class="paren">(</span>7<span class="paren">)</span></span> A new drug application, described in part 314.</p>
</div>
<div id="p-50.3(b)(8)">
<p class="indent-2" data-title="50.3(b)(8)"><span class="paragraph-hierarchy"><span class="paren">(</span>8<span class="paren">)</span></span> Data and information about the bioavailability or bioequivalence of drugs for human use submitted as part of the procedures for issuing, amending, or repealing a bioequivalence requirement, described in part 320.</p>
</div>
<div id="p-50.3(b)(9)">
<p class="indent-2" data-title="50.3(b)(9)"><span class="paragraph-hierarchy"><span class="paren">(</span>9<span class="paren">)</span></span> Data and information about an over-the-counter drug for human use submitted as part of the procedures for classifying these drugs as generally recognized as safe and effective and not misbranded, described in part 330.</p>
</div>
<div id="p-50.3(b)(10)">
<p class="indent-2" data-title="50.3(b)(10)"><span class="paragraph-hierarchy"><span class="paren">(</span>10<span class="paren">)</span></span> Data and information about a prescription drug for human use submitted as part of the procedures for classifying these drugs as generally recognized as safe and effective and not misbranded, described in this chapter.</p>
</div>
<div id="p-50.3(b)(11)">
<p class="indent-2" data-title="50.3(b)(11)"><span class="paragraph-hierarchy"><span class="paren">(</span>11<span class="paren">)</span></span> [Reserved]</p>
</div>
<div id="p-50.3(b)(12)">
<p class="indent-2" data-title="50.3(b)(12)"><span class="paragraph-hierarchy"><span class="paren">(</span>12<span class="paren">)</span></span> An application for a biologics license, described in <a href="/current/title-21/part-601" class="cfr external">part 601 of this chapter</a>.</p>
</div>
<div id="p-50.3(b)(13)">
<p class="indent-2" data-title="50.3(b)(13)"><span class="paragraph-hierarchy"><span class="paren">(</span>13<span class="paren">)</span></span> Data and information about a biological product submitted as part of the procedures for determining that licensed biological products are safe and effective and not misbranded, described in part 601.</p>
</div>
<div id="p-50.3(b)(14)">
<p class="indent-2" data-title="50.3(b)(14)"><span class="paragraph-hierarchy"><span class="paren">(</span>14<span class="paren">)</span></span> Data and information about an in vitro diagnostic product submitted as part of the procedures for establishing, amending, or repealing a standard for these products, described in part 809.</p>
</div>
<div id="p-50.3(b)(15)">
<p class="indent-2" data-title="50.3(b)(15)"><span class="paragraph-hierarchy"><span class="paren">(</span>15<span class="paren">)</span></span> An <em>Application for an Investigational Device Exemption,</em> described in part 812.</p>
</div>
<div id="p-50.3(b)(16)">
<p class="indent-2" data-title="50.3(b)(16)"><span class="paragraph-hierarchy"><span class="paren">(</span>16<span class="paren">)</span></span> Data and information about a medical device submitted as part of the procedures for classifying these devices, described in section 513.</p>
</div>
<div id="p-50.3(b)(17)">
<p class="indent-2" data-title="50.3(b)(17)"><span class="paragraph-hierarchy"><span class="paren">(</span>17<span class="paren">)</span></span> Data and information about a medical device submitted as part of the procedures for establishing, amending, or repealing a standard for these devices, described in section 514.</p>
</div>
<div id="p-50.3(b)(18)">
<p class="indent-2" data-title="50.3(b)(18)"><span class="paragraph-hierarchy"><span class="paren">(</span>18<span class="paren">)</span></span> An application for premarket approval of a medical device, described in section 515.</p>
</div>
<div id="p-50.3(b)(19)">
<p class="indent-2" data-title="50.3(b)(19)"><span class="paragraph-hierarchy"><span class="paren">(</span>19<span class="paren">)</span></span> A product development protocol for a medical device, described in section 515.</p>
</div>
<div id="p-50.3(b)(20)">
<p class="indent-2" data-title="50.3(b)(20)"><span class="paragraph-hierarchy"><span class="paren">(</span>20<span class="paren">)</span></span> Data and information about an electronic product submitted as part of the procedures for establishing, amending, or repealing a standard for these products, described in section 358 of the Public Health Service Act.</p>
</div>
<div id="p-50.3(b)(21)">
<p class="indent-2" data-title="50.3(b)(21)"><span class="paragraph-hierarchy"><span class="paren">(</span>21<span class="paren">)</span></span> Data and information about an electronic product submitted as part of the procedures for obtaining a variance from any electronic product performance standard, as described in <a href="/current/title-21/section-1010.4" class="cfr external">§ 1010.4</a>.</p>
</div>
<div id="p-50.3(b)(22)">
<p class="indent-2" data-title="50.3(b)(22)"><span class="paragraph-hierarchy"><span class="paren">(</span>22<span class="paren">)</span></span> Data and information about an electronic product submitted as part of the procedures for granting, amending, or extending an exemption from a radiation safety performance standard, as described in <a href="/current/title-21/section-1010.5" class="cfr external">§ 1010.5</a>.</p>
</div>
<div id="p-50.3(b)(23)">
<p class="indent-2" data-title="50.3(b)(23)"><span class="paragraph-hierarchy"><span class="paren">(</span>23<span class="paren">)</span></span> Data and information about a clinical study of an infant formula when submitted as part of an infant formula notification under section 412(c) of the Federal Food, Drug, and Cosmetic Act.</p>
</div>
<div id="p-50.3(b)(24)">
<p class="indent-2" data-title="50.3(b)(24)"><span class="paragraph-hierarchy"><span class="paren">(</span>24<span class="paren">)</span></span> Data and information submitted in a petition for a nutrient content claim, described in <a href="/current/title-21/section-101.69" class="cfr external">§ 101.69 of this chapter</a>, or for a health claim, described in <a href="/current/title-21/section-101.70" class="cfr external">§ 101.70 of this chapter</a>.</p>
</div>
<div id="p-50.3(b)(25)">
<p class="indent-2" data-title="50.3(b)(25)"><span class="paragraph-hierarchy"><span class="paren">(</span>25<span class="paren">)</span></span> Data and information from investigations involving children submitted in a new dietary ingredient notification, described in <a href="/current/title-21/section-190.6" class="cfr external">§ 190.6 of this chapter</a>.</p>
</div>
</div>
<div id="p-50.3(c)">
<p class="indent-1" data-title="50.3(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">Clinical investigation</em>  means any experiment that involves a test article and one or more human subjects and that either is subject to requirements for prior submission to the Food and Drug Administration under section 505(i) or 520(g) of the act, or is not subject to requirements for prior submission to the Food and Drug Administration under these sections of the act, but the results of which are intended to be submitted later to, or held for inspection by, the Food and Drug Administration as part of an application for a research or marketing permit. The term does not include experiments that are subject to the provisions of <a href="/current/title-21/part-58" class="cfr external">part 58 of this chapter</a>, regarding nonclinical laboratory studies.</p>
</div>
<div id="p-50.3(d)">
<p class="indent-1" data-title="50.3(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> <em class="paragraph-heading">Investigator</em>  means an individual who actually conducts a clinical investigation, i.e., under whose immediate direction the test article is administered or dispensed to, or used involving, a subject, or, in the event of an investigation conducted by a team of individuals, is the responsible leader of that team.</p>
</div>
<div id="p-50.3(e)">
<p class="indent-1" data-title="50.3(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> <em class="paragraph-heading">Sponsor</em>  means a person who initiates a clinical investigation, but who does not actually conduct the investigation, i.e., the test article is administered or dispensed to or used involving, a subject under the immediate direction of another individual. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct a clinical investigation it has initiated is considered to be a sponsor (not a sponsor-investigator), and the employees are considered to be investigators.</p>
</div>
<div id="p-50.3(f)">
<p class="indent-1" data-title="50.3(f)"><span class="paragraph-hierarchy"><span class="paren">(</span>f<span class="paren">)</span></span> <em class="paragraph-heading">Sponsor-investigator</em>  means an individual who both initiates and actually conducts, alone or with others, a clinical investigation, i.e., under whose immediate direction the test article is administered or dispensed to, or used involving, a subject. The term does not include any person other than an individual, e.g., corporation or agency.</p>
</div>
<div id="p-50.3(g)">
<p class="indent-1" data-title="50.3(g)"><span class="paragraph-hierarchy"><span class="paren">(</span>g<span class="paren">)</span></span> <em class="paragraph-heading">Human subject</em>  means an individual who is or becomes a participant in research, either as a recipient of the test article or as a control. A subject may be either a healthy human or a patient.</p>
</div>
<div id="p-50.3(h)">
<p class="indent-1" data-title="50.3(h)"><span class="paragraph-hierarchy"><span class="paren">(</span>h<span class="paren">)</span></span> <em class="paragraph-heading">Institution</em>  means any public or private entity or agency (including Federal, State, and other agencies). The word <em>facility</em> as used in section 520(g) of the act is deemed to be synonymous with the term <em>institution</em> for purposes of this part.</p>
</div>
<div id="p-50.3(i)">
<p class="indent-1" data-title="50.3(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> <em class="paragraph-heading">Institutional review board</em>  (IRB) means any board, committee, or other group formally designated by an institution to review biomedical research involving humans as subjects, to approve the initiation of and conduct periodic review of such research. The term has the same meaning as the phrase <em>institutional review committee</em> as used in section 520(g) of the act.</p>
</div>
<div id="p-50.3(j)">
<p class="indent-1" data-title="50.3(j)"><span class="paragraph-hierarchy"><span class="paren">(</span>j<span class="paren">)</span></span> <em class="paragraph-heading">Test article</em>  means any drug (including a biological product for human use), medical device for human use, human food additive, color additive, electronic product, or any other article subject to regulation under the act or under sections 351 and 354-360F of the Public Health Service Act (<a href="https://www.govinfo.gov/link/uscode/42/262" class="usc external" target="_blank" rel="noopener noreferrer">42 U.S.C. 262</a> and <a href="https://www.govinfo.gov/link/uscode/42/263b" class="usc external" target="_blank" rel="noopener noreferrer">263b-263n</a>).</p>
</div>
<div id="p-50.3(k)">
<p class="indent-1" data-title="50.3(k)"><span class="paragraph-hierarchy"><span class="paren">(</span>k<span class="paren">)</span></span> <em class="paragraph-heading">Minimal risk</em>  means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.</p>
</div>
<div id="p-50.3(l)">
<p class="indent-1" data-title="50.3(l)"><span class="paragraph-hierarchy"><span class="paren">(</span>l<span class="paren">)</span></span> <em class="paragraph-heading">Legally authorized representative</em>  means an individual or judicial or other body authorized under applicable law to consent on behalf of a prospective subject to the subject's particpation in the procedure(s) involved in the research.</p>
</div>
<div id="p-50.3(m)">
<p class="indent-1" data-title="50.3(m)"><span class="paragraph-hierarchy"><span class="paren">(</span>m<span class="paren">)</span></span> <em class="paragraph-heading">Family member</em>  means any one of the following legally competent persons: Spouse; parents; children (including adopted children); brothers, sisters, and spouses of brothers and sisters; and any individual related by blood or affinity whose close association with the subject is the equivalent of a family relationship.</p>
</div>
<div id="p-50.3(n)">
<p class="indent-1" data-title="50.3(n)"><span class="paragraph-hierarchy"><span class="paren">(</span>n<span class="paren">)</span></span> <em class="paragraph-heading">Assent</em>  means a child's affirmative agreement to participate in a clinical investigation. Mere failure to object should not, absent affirmative agreement, be construed as assent.</p>
</div>
<div id="p-50.3(o)">
<p class="indent-1" data-title="50.3(o)"><span class="paragraph-hierarchy"><span class="paren">(</span>o<span class="paren">)</span></span> <em class="paragraph-heading">Children</em>  means persons who have not attained the legal age for consent to treatments or procedures involved in clinical investigations, under the applicable law of the jurisdiction in which the clinical investigation will be conducted.</p>
</div>
<div id="p-50.3(p)">
<p class="indent-1" data-title="50.3(p)"><span class="paragraph-hierarchy"><span class="paren">(</span>p<span class="paren">)</span></span> <em class="paragraph-heading">Parent</em>  means a child's biological or adoptive parent.</p>
</div>
<div id="p-50.3(q)">
<p class="indent-1" data-title="50.3(q)"><span class="paragraph-hierarchy"><span class="paren">(</span>q<span class="paren">)</span></span> <em class="paragraph-heading">Ward</em>  means a child who is placed in the legal custody of the State or other agency, institution, or entity, consistent with applicable Federal, State, or local law.</p>
</div>
<div id="p-50.3(r)">
<p class="indent-1" data-title="50.3(r)"><span class="paragraph-hierarchy"><span class="paren">(</span>r<span class="paren">)</span></span> <em class="paragraph-heading">Permission</em>  means the agreement of parent(s) or guardian to the participation of their child or ward in a clinical investigation.</p>
</div>
<div id="p-50.3(s)"><p class="indent-1" data-title="50.3(s)"><span class="paragraph-hierarchy"><span class="paren">(</span>s<span class="paren">)</span></span> <em class="paragraph-heading">Guardian</em>  means an individual who is authorized under applicable State or local law to consent on behalf of a child to general medical care.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/45-FR-36390" class="fr-reference" data-reference="45 FR 36390">45 FR 36390</a>, May 30, 1980, as amended at <a href="https://www.federalregister.gov/citation/46-FR-8950" class="fr-reference" data-reference="46 FR 8950">46 FR 8950</a>, Jan. 27, 1981; <a href="https://www.federalregister.gov/citation/54-FR-9038" class="fr-reference" data-reference="54 FR 9038">54 FR 9038</a>, Mar. 3, 1989; <a href="https://www.federalregister.gov/citation/56-FR-28028" class="fr-reference" data-reference="56 FR 28028">56 FR 28028</a>, June 18, 1991; <a href="https://www.federalregister.gov/citation/61-FR-51528" class="fr-reference" data-reference="61 FR 51528">61 FR 51528</a>, Oct. 2, 1996; <a href="https://www.federalregister.gov/citation/62-FR-39440" class="fr-reference" data-reference="62 FR 39440">62 FR 39440</a>, July 23, 1997; <a href="https://www.federalregister.gov/citation/64-FR-399" class="fr-reference" data-reference="64 FR 399">64 FR 399</a>, Jan. 5, 1999; <a href="https://www.federalregister.gov/citation/64-FR-56448" class="fr-reference" data-reference="64 FR 56448">64 FR 56448</a>, Oct. 20, 1999; <a href="https://www.federalregister.gov/citation/66-FR-20597" class="fr-reference" data-reference="66 FR 20597">66 FR 20597</a>, Apr. 24, 2001; <a href="https://www.federalregister.gov/citation/78-FR-12950" class="fr-reference" data-reference="78 FR 12950">78 FR 12950</a>, Feb. 26, 2013]
</p>
</div>

</div>

<div class="subpart" id="subpart-B"><h2 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-50/subpart-B&quot;,&quot;citation&quot;:&quot;21 CFR Part 50 Subpart B&quot;}">Subpart B—Informed Consent of Human Subjects</h2>

<div class="source"><h4 class="inline-header">Source:</h4><p class="inline-paragraph"><a href="https://www.federalregister.gov/citation/46-FR-8951" class="fr-reference" data-reference="46 FR 8951">46 FR 8951</a>, Jan. 27, 1981, unless otherwise noted.
</p></div>
<div class="section" id="50.20">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.20","citation":"21 CFR 50.20"}'>§ 50.20 General requirements for informed consent.</h4>
<p>Except as provided in <a href="/current/title-21/section-50.22" class="cfr external">§§ 50.22</a>, <a href="/current/title-21/section-50.23" class="cfr external">50.23</a>, and <a href="/current/title-21/section-50.24" class="cfr external">50.24</a>, no investigator may involve a human being as a subject in research covered by these regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative. An investigator shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence. The information that is given to the subject or the representative shall be in language understandable to the subject or the representative. No informed consent, whether oral or written, may include any exculpatory language through which the subject or the representative is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution, or its agents from liability for negligence.</p>
<p class="citation">[<a href="https://www.federalregister.gov/citation/46-FR-8951" class="fr-reference" data-reference="46 FR 8951">46 FR 8951</a>, Jan. 27, 1981, as amended at <a href="https://www.federalregister.gov/citation/64-FR-10942" class="fr-reference" data-reference="64 FR 10942">64 FR 10942</a>, Mar. 8, 1999; <a href="https://www.federalregister.gov/citation/88-FR-88248" class="fr-reference" data-reference="88 FR 88248">88 FR 88248</a>, Dec. 21, 2023]
</p>
</div>

<div class="section" id="50.22">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.22","citation":"21 CFR 50.22"}'>§ 50.22 Exception from informed consent requirements for minimal risk clinical investigations.</h4>
<p>The IRB responsible for the review, approval, and continuing review of the clinical investigation described in this section may approve an informed consent procedure that does not include or that alters some or all of the elements of informed consent set forth in <a href="/current/title-21/section-50.25#p-50.25(a)" class="cfr external">§ 50.25(a)</a> and <a href="/current/title-21/section-50.25#p-50.25(b)" class="cfr external">(b)</a>, or may waive the requirement to obtain informed consent, provided the IRB finds and documents the following:</p>
<div id="p-50.22(a)">
<p class="indent-1" data-title="50.22(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> The clinical investigation involves no more than minimal risk to the subjects;</p>
</div>
<div id="p-50.22(b)">
<p class="indent-1" data-title="50.22(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> The clinical investigation could not practicably be carried out without the requested waiver or alteration;</p>
</div>
<div id="p-50.22(c)">
<p class="indent-1" data-title="50.22(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> If the clinical investigation involves using identifiable private information or identifiable biospecimens, the clinical investigation could not practicably be carried out without using such information or biospecimens in an identifiable format;</p>
</div>
<div id="p-50.22(d)">
<p class="indent-1" data-title="50.22(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> The waiver or alteration will not adversely affect the rights and welfare of the subjects; and</p>
</div>
<div id="p-50.22(e)"><p class="indent-1" data-title="50.22(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> Whenever appropriate, the subjects or legally authorized representatives will be provided with additional pertinent information after participation.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/88-FR-88248" class="fr-reference" data-reference="88 FR 88248">88 FR 88248</a>, Dec. 21, 2023]
</p>
</div>

<div class="section" id="50.23">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.23","citation":"21 CFR 50.23"}'>§ 50.23 Exception from general requirements.</h4>
<div id="p-50.23(a)">
<p class="indent-1" data-title="50.23(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> The obtaining of informed consent shall be deemed feasible unless, before use of the test article (except as provided in <a href="/current/title-21/section-50.23#p-50.23(b)" class="cfr external">paragraph (b)</a> of this section), both the investigator and a physician who is not otherwise participating in the clinical investigation certify in writing all of the following:</p>
<div id="p-50.23(a)(1)">
<p class="indent-2" data-title="50.23(a)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> The human subject is confronted by a life-threatening situation necessitating the use of the test article.</p>
</div>
<div id="p-50.23(a)(2)">
<p class="indent-2" data-title="50.23(a)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Informed consent cannot be obtained from the subject because of an inability to communicate with, or obtain legally effective consent from, the subject.</p>
</div>
<div id="p-50.23(a)(3)">
<p class="indent-2" data-title="50.23(a)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> Time is not sufficient to obtain consent from the subject's legal representative.</p>
</div>
<div id="p-50.23(a)(4)">
<p class="indent-2" data-title="50.23(a)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> There is available no alternative method of approved or generally recognized therapy that provides an equal or greater likelihood of saving the life of the subject.</p>
</div>
</div>
<div id="p-50.23(b)">
<p class="indent-1" data-title="50.23(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> If immediate use of the test article is, in the investigator's opinion, required to preserve the life of the subject, and time is not sufficient to obtain the independent determination required in <a href="/current/title-21/section-50.23#p-50.23(a)" class="cfr external">paragraph (a)</a> of this section in advance of using the test article, the determinations of the clinical investigator shall be made and, within 5 working days after the use of the article, be reviewed and evaluated in writing by a physician who is not participating in the clinical investigation.</p>
</div>
<div id="p-50.23(c)">
<p class="indent-1" data-title="50.23(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> The documentation required in <a href="/current/title-21/section-50.23#p-50.23(a)" class="cfr external">paragraph (a)</a> or <a href="/current/title-21/section-50.23#p-50.23(b)" class="cfr external">(b)</a> of this section shall be submitted to the IRB within 5 working days after the use of the test article.</p>
</div>
<div id="p-50.23(d)">
<p class="indent-1" data-title="50.23(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> </p>
<div id="p-50.23(d)(1)">
<p class="indent-2" data-title="50.23(d)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Under <a href="https://www.govinfo.gov/link/uscode/10/1107" class="usc external" target="_blank" rel="noopener noreferrer">10 U.S.C. 1107(f)</a> the President may waive the prior consent requirement for the administration of an investigational new drug to a member of the armed forces in connection with the member's participation in a particular military operation. The statute specifies that only the President may waive informed consent in this connection and the President may grant such a waiver only if the President determines in writing that obtaining consent: Is not feasible; is contrary to the best interests of the military member; or is not in the interests of national security. The statute further provides that in making a determination to waive prior informed consent on the ground that it is not feasible or the ground that it is contrary to the best interests of the military members involved, the President shall apply the standards and criteria that are set forth in the relevant FDA regulations for a waiver of the prior informed consent requirements of section 505(i)(4) of the Federal Food, Drug, and Cosmetic Act (<a href="https://www.govinfo.gov/link/uscode/21/355" class="usc external" target="_blank" rel="noopener noreferrer">21 U.S.C. 355(i)(4)</a>). Before such a determination may be made that obtaining informed consent from military personnel prior to the use of an investigational drug (including an antibiotic or biological product) in a specific protocol under an investigational new drug application (IND) sponsored by the Department of Defense (DOD) and limited to specific military personnel involved in a particular military operation is not feasible or is contrary to the best interests of the military members involved the Secretary of Defense must first request such a determination from the President, and certify and document to the President that the following standards and criteria contained in <a href="/current/title-21/section-50.23#p-50.23(d)(1)" class="cfr external">paragraphs (d)(1)</a> through <a href="/current/title-21/section-50.23#p-50.23(d)(4)" class="cfr external">(d)(4)</a> of this section have been met.</p>
<div id="p-50.23(d)(1)(i)">
<p class="indent-3" data-title="50.23(d)(1)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The extent and strength of evidence of the safety and effectiveness of the investigational new drug in relation to the medical risk that could be encountered during the military operation supports the drug's administration under an IND.</p>
</div>
<div id="p-50.23(d)(1)(ii)">
<p class="indent-3" data-title="50.23(d)(1)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> The military operation presents a substantial risk that military personnel may be subject to a chemical, biological, nuclear, or other exposure likely to produce death or serious or life-threatening injury or illness.</p>
</div>
<div id="p-50.23(d)(1)(iii)">
<p class="indent-3" data-title="50.23(d)(1)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> There is no available satisfactory alternative therapeutic or preventive treatment in relation to the intended use of the investigational new drug.</p>
</div>
<div id="p-50.23(d)(1)(iv)">
<p class="indent-3" data-title="50.23(d)(1)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Conditioning use of the investigational new drug on the voluntary participation of each member could significantly risk the safety and health of any individual member who would decline its use, the safety of other military personnel, and the accomplishment of the military mission.</p>
</div>
<div id="p-50.23(d)(1)(v)">
<p class="indent-3" data-title="50.23(d)(1)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> A duly constituted institutional review board (IRB) established and operated in accordance with the requirements of <a href="/current/title-21/section-50.23#p-50.23(d)(2)" class="cfr external">paragraphs (d)(2)</a> and <a href="/current/title-21/section-50.23#p-50.23(d)(3)" class="cfr external">(d)(3)</a> of this section, responsible for review of the study, has reviewed and approved the investigational new drug protocol and the administration of the investigational new drug without informed consent. DOD's request is to include the documentation required by <a href="/current/title-21/section-56.115#p-56.115(a)(2)" class="cfr external">§ 56.115(a)(2) of this chapter</a>.</p>
</div>
<div id="p-50.23(d)(1)(vi)">
<p class="indent-3" data-title="50.23(d)(1)(vi)"><span class="paragraph-hierarchy"><span class="paren">(</span>vi<span class="paren">)</span></span> DOD has explained:</p>
<div id="p-50.23(d)(1)(vi)(A)">
<p class="indent-4" data-title="50.23(d)(1)(vi)(A)"><span class="paragraph-hierarchy"><span class="paren">(</span>A<span class="paren">)</span></span> The context in which the investigational drug will be administered, e.g., the setting or whether it will be self-administered or it will be administered by a health professional;</p>
</div>
<div id="p-50.23(d)(1)(vi)(B)">
<p class="indent-4" data-title="50.23(d)(1)(vi)(B)"><span class="paragraph-hierarchy"><span class="paren">(</span>B<span class="paren">)</span></span> The nature of the disease or condition for which the preventive or therapeutic treatment is intended; and</p>
</div>
<div id="p-50.23(d)(1)(vi)(C)">
<p class="indent-4" data-title="50.23(d)(1)(vi)(C)"><span class="paragraph-hierarchy"><span class="paren">(</span>C<span class="paren">)</span></span> To the extent there are existing data or information available, information on conditions that could alter the effects of the investigational drug.</p>
</div>
</div>
<div id="p-50.23(d)(1)(vii)">
<p class="indent-3" data-title="50.23(d)(1)(vii)"><span class="paragraph-hierarchy"><span class="paren">(</span>vii<span class="paren">)</span></span> DOD's recordkeeping system is capable of tracking and will be used to track the proposed treatment from supplier to the individual recipient.</p>
</div>
<div id="p-50.23(d)(1)(viii)">
<p class="indent-3" data-title="50.23(d)(1)(viii)"><span class="paragraph-hierarchy"><span class="paren">(</span>viii<span class="paren">)</span></span> Each member involved in the military operation will be given, prior to the administration of the investigational new drug, a specific written information sheet (including information required by <a href="https://www.govinfo.gov/link/uscode/10/1107" class="usc external" target="_blank" rel="noopener noreferrer">10 U.S.C. 1107(d)</a>) concerning the investigational new drug, the risks and benefits of its use, potential side effects, and other pertinent information about the appropriate use of the product.</p>
</div>
<div id="p-50.23(d)(1)(ix)">
<p class="indent-3" data-title="50.23(d)(1)(ix)"><span class="paragraph-hierarchy"><span class="paren">(</span>ix<span class="paren">)</span></span> Medical records of members involved in the military operation will accurately document the receipt by members of the notification required by <a href="/current/title-21/section-50.23#p-50.23(d)(1)(viii)" class="cfr external">paragraph (d)(1)(viii)</a> of this section.</p>
</div>
<div id="p-50.23(d)(1)(x)">
<p class="indent-3" data-title="50.23(d)(1)(x)"><span class="paragraph-hierarchy"><span class="paren">(</span>x<span class="paren">)</span></span> Medical records of members involved in the military operation will accurately document the receipt by members of any investigational new drugs in accordance with FDA regulations including <a href="/current/title-21/part-312" class="cfr external">part 312 of this chapter</a>.</p>
</div>
<div id="p-50.23(d)(1)(xi)">
<p class="indent-3" data-title="50.23(d)(1)(xi)"><span class="paragraph-hierarchy"><span class="paren">(</span>xi<span class="paren">)</span></span> DOD will provide adequate followup to assess whether there are beneficial or adverse health consequences that result from the use of the investigational product.</p>
</div>
<div id="p-50.23(d)(1)(xii)">
<p class="indent-3" data-title="50.23(d)(1)(xii)"><span class="paragraph-hierarchy"><span class="paren">(</span>xii<span class="paren">)</span></span> DOD is pursuing drug development, including a time line, and marketing approval with due diligence.</p>
</div>
<div id="p-50.23(d)(1)(xiii)">
<p class="indent-3" data-title="50.23(d)(1)(xiii)"><span class="paragraph-hierarchy"><span class="paren">(</span>xiii<span class="paren">)</span></span> FDA has concluded that the investigational new drug protocol may proceed subject to a decision by the President on the informed consent waiver request.</p>
</div>
<div id="p-50.23(d)(1)(xiv)">
<p class="indent-3" data-title="50.23(d)(1)(xiv)"><span class="paragraph-hierarchy"><span class="paren">(</span>xiv<span class="paren">)</span></span> DOD will provide training to the appropriate medical personnel and potential recipients on the specific investigational new drug to be administered prior to its use.</p>
</div>
<div id="p-50.23(d)(1)(xv)">
<p class="indent-3" data-title="50.23(d)(1)(xv)"><span class="paragraph-hierarchy"><span class="paren">(</span>xv<span class="paren">)</span></span> DOD has stated and justified the time period for which the waiver is needed, not to exceed one year, unless separately renewed under these standards and criteria.</p>
</div>
<div id="p-50.23(d)(1)(xvi)">
<p class="indent-3" data-title="50.23(d)(1)(xvi)"><span class="paragraph-hierarchy"><span class="paren">(</span>xvi<span class="paren">)</span></span> DOD shall have a continuing obligation to report to the FDA and to the President any changed circumstances relating to these standards and criteria (including the time period referred to in <a href="/current/title-21/section-50.23#p-50.23(d)(1)(xv)" class="cfr external">paragraph (d)(1)(xv)</a> of this section) or that otherwise might affect the determination to use an investigational new drug without informed consent.</p>
</div>
<div id="p-50.23(d)(1)(xvii)">
<p class="indent-3" data-title="50.23(d)(1)(xvii)"><span class="paragraph-hierarchy"><span class="paren">(</span>xvii<span class="paren">)</span></span> DOD is to provide public notice as soon as practicable and consistent with classification requirements through notice in the <span class="minor-caps">Federal Register</span> describing each waiver of informed consent determination, a summary of the most updated scientific information on the products used, and other pertinent information.</p>
</div>
<div id="p-50.23(d)(1)(xviii)">
<p class="indent-3" data-title="50.23(d)(1)(xviii)"><span class="paragraph-hierarchy"><span class="paren">(</span>xviii<span class="paren">)</span></span> Use of the investigational drug without informed consent otherwise conforms with applicable law.</p>
</div>
</div>
<div id="p-50.23(d)(2)">
<p class="indent-2" data-title="50.23(d)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> The duly constituted institutional review board, described in <a href="/current/title-21/section-50.23#p-50.23(d)(1)(v)" class="cfr external">paragraph (d)(1)(v)</a> of this section, must include at least 3 nonaffiliated members who shall not be employees or officers of the Federal Government (other than for purposes of membership on the IRB) and shall be required to obtain any necessary security clearances. This IRB shall review the proposed IND protocol at a convened meeting at which a majority of the members are present including at least one member whose primary concerns are in nonscientific areas and, if feasible, including a majority of the nonaffiliated members. The information required by <a href="/current/title-21/section-56.115#p-56.115(a)(2)" class="cfr external">§ 56.115(a)(2) of this chapter</a> is to be provided to the Secretary of Defense for further review.</p>
</div>
<div id="p-50.23(d)(3)">
<p class="indent-2" data-title="50.23(d)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> The duly constituted institutional review board, described in <a href="/current/title-21/section-50.23#p-50.23(d)(1)(v)" class="cfr external">paragraph (d)(1)(v)</a> of this section, must review and approve:</p>
<div id="p-50.23(d)(3)(i)">
<p class="indent-3" data-title="50.23(d)(3)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The required information sheet;</p>
</div>
<div id="p-50.23(d)(3)(ii)">
<p class="indent-3" data-title="50.23(d)(3)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> The adequacy of the plan to disseminate information, including distribution of the information sheet to potential recipients, on the investigational product (e.g., in forms other than written);</p>
</div>
<div id="p-50.23(d)(3)(iii)">
<p class="indent-3" data-title="50.23(d)(3)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> The adequacy of the information and plans for its dissemination to health care providers, including potential side effects, contraindications, potential interactions, and other pertinent considerations; and</p>
</div>
<div id="p-50.23(d)(3)(iv)">
<p class="indent-3" data-title="50.23(d)(3)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> An informed consent form as required by <a href="/current/title-21/part-50" class="cfr external">part 50 of this chapter</a>, in those circumstances in which DOD determines that informed consent may be obtained from some or all personnel involved.</p>
</div>
</div>
<div id="p-50.23(d)(4)">
<p class="indent-2" data-title="50.23(d)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> DOD is to submit to FDA summaries of institutional review board meetings at which the proposed protocol has been reviewed.</p>
</div>
<div id="p-50.23(d)(5)">
<p class="indent-2" data-title="50.23(d)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> Nothing in these criteria or standards is intended to preempt or limit FDA's and DOD's authority or obligations under applicable statutes and regulations.</p>
</div>
</div>
<div id="p-50.23(e)">
<p class="indent-1" data-title="50.23(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> </p>
<div id="p-50.23(e)(1)">
<p class="indent-2" data-title="50.23(e)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Obtaining informed consent for investigational in vitro diagnostic devices used to identify chemical, biological, radiological, or nuclear agents will be deemed feasible unless, before use of the test article, both the investigator (e.g., clinical laboratory director or other responsible individual) and a physician who is not otherwise participating in the clinical investigation make the determinations and later certify in writing all of the following:</p>
<div id="p-50.23(e)(1)(i)">
<p class="indent-3" data-title="50.23(e)(1)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The human subject is confronted by a life-threatening situation necessitating the use of the investigational in vitro diagnostic device to identify a chemical, biological, radiological, or nuclear agent that would suggest a terrorism event or other public health emergency.</p>
</div>
<div id="p-50.23(e)(1)(ii)">
<p class="indent-3" data-title="50.23(e)(1)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Informed consent cannot be obtained from the subject because:</p>
<div id="p-50.23(e)(1)(ii)(A)">
<p class="indent-4" data-title="50.23(e)(1)(ii)(A)"><span class="paragraph-hierarchy"><span class="paren">(</span>A<span class="paren">)</span></span> There was no reasonable way for the person directing that the specimen be collected to know, at the time the specimen was collected, that there would be a need to use the investigational in vitro diagnostic device on that subject's specimen; and</p>
</div>
<div id="p-50.23(e)(1)(ii)(B)">
<p class="indent-4" data-title="50.23(e)(1)(ii)(B)"><span class="paragraph-hierarchy"><span class="paren">(</span>B<span class="paren">)</span></span> Time is not sufficient to obtain consent from the subject without risking the life of the subject.</p>
</div>
</div>
<div id="p-50.23(e)(1)(iii)">
<p class="indent-3" data-title="50.23(e)(1)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Time is not sufficient to obtain consent from the subject's legally authorized representative.</p>
</div>
<div id="p-50.23(e)(1)(iv)">
<p class="indent-3" data-title="50.23(e)(1)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> There is no cleared or approved available alternative method of diagnosis, to identify the chemical, biological, radiological, or nuclear agent that provides an equal or greater likelihood of saving the life of the subject.</p>
</div>
</div>
<div id="p-50.23(e)(2)">
<p class="indent-2" data-title="50.23(e)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> If use of the investigational device is, in the opinion of the investigator (e.g., clinical laboratory director or other responsible person), required to preserve the life of the subject, and time is not sufficient to obtain the independent determination required in <a href="/current/title-21/section-50.23#p-50.23(e)(1)" class="cfr external">paragraph (e)(1)</a> of this section in advance of using the investigational device, the determinations of the investigator shall be made and, within 5 working days after the use of the device, be reviewed and evaluated in writing by a physician who is not participating in the clinical investigation.</p>
</div>
<div id="p-50.23(e)(3)">
<p class="indent-2" data-title="50.23(e)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> The investigator must submit the written certification of the determinations made by the investigator and an independent physician required in <a href="/current/title-21/section-50.23#p-50.23(e)(1)" class="cfr external">paragraph (e)(1)</a> or <a href="/current/title-21/section-50.23#p-50.23(e)(2)" class="cfr external">(e)(2)</a> of this section to the IRB and FDA within 5 working days after the use of the device.</p>
</div>
<div id="p-50.23(e)(4)">
<p class="indent-2" data-title="50.23(e)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> An investigator must disclose the investigational status of the in vitro diagnostic device and what is known about the performance characteristics of the device in the report to the subject's health care provider and in any report to public health authorities. The investigator must provide the IRB with the information required in <a href="/current/title-21/section-50.25" class="cfr external">§ 50.25</a> (except for the information described in <a href="/current/title-21/section-50.25#p-50.25(a)(8)" class="cfr external">§ 50.25(a)(8)</a>) and the procedures that will be used to provide this information to each subject or the subject's legally authorized representative at the time the test results are provided to the subject's health care provider and public health authorities.</p>
</div>
<div id="p-50.23(e)(5)">
<p class="indent-2" data-title="50.23(e)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> The IRB is responsible for ensuring the adequacy of the information required in <a href="/current/title-21/section-50.25" class="cfr external">section 50.25</a> (except for the information described in <a href="/current/title-21/section-50.25#p-50.25(a)(8)" class="cfr external">§ 50.25(a)(8)</a>) and for ensuring that procedures are in place to provide this information to each subject or the subject's legally authorized representative.</p>
</div>
<div id="p-50.23(e)(6)"><p class="indent-2" data-title="50.23(e)(6)"><span class="paragraph-hierarchy"><span class="paren">(</span>6<span class="paren">)</span></span> No State or political subdivision of a State may establish or continue in effect any law, rule, regulation or other requirement that informed consent be obtained before an investigational in vitro diagnostic device may be used to identify chemical, biological, radiological, or nuclear agent in suspected terrorism events and other potential public health emergencies that is different from, or in addition to, the requirements of this regulation.</p></div>
</div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/46-FR-8951" class="fr-reference" data-reference="46 FR 8951">46 FR 8951</a>, Jan. 27, 1981, as amended at <a href="https://www.federalregister.gov/citation/55-FR-52817" class="fr-reference" data-reference="55 FR 52817">55 FR 52817</a>, Dec. 21, 1990; <a href="https://www.federalregister.gov/citation/64-FR-399" class="fr-reference" data-reference="64 FR 399">64 FR 399</a>, Jan. 5, 1999; <a href="https://www.federalregister.gov/citation/64-FR-54188" class="fr-reference" data-reference="64 FR 54188">64 FR 54188</a>, Oct. 5, 1999; <a href="https://www.federalregister.gov/citation/71-FR-32833" class="fr-reference" data-reference="71 FR 32833">71 FR 32833</a>, June 7, 2006; <a href="https://www.federalregister.gov/citation/76-FR-36993" class="fr-reference" data-reference="76 FR 36993">76 FR 36993</a>, June 24, 2011]
</p>
</div>

<div class="section" id="50.24">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.24","citation":"21 CFR 50.24"}'>§ 50.24 Exception from informed consent requirements for emergency research.</h4>
<div id="p-50.24(a)">
<p class="indent-1" data-title="50.24(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> The IRB responsible for the review, approval, and continuing review of the clinical investigation described in this section may approve that investigation without requiring that informed consent of all research subjects be obtained if the IRB (with the concurrence of a licensed physician who is a member of or consultant to the IRB and who is not otherwise participating in the clinical investigation) finds and documents each of the following:</p>
<div id="p-50.24(a)(1)">
<p class="indent-2" data-title="50.24(a)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> The human subjects are in a life-threatening situation, available treatments are unproven or unsatisfactory, and the collection of valid scientific evidence, which may include evidence obtained through randomized placebo-controlled investigations, is necessary to determine the safety and effectiveness of particular interventions.</p>
</div>
<div id="p-50.24(a)(2)">
<p class="indent-2" data-title="50.24(a)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Obtaining informed consent is not feasible because:</p>
<div id="p-50.24(a)(2)(i)">
<p class="indent-3" data-title="50.24(a)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The subjects will not be able to give their informed consent as a result of their medical condition;</p>
</div>
<div id="p-50.24(a)(2)(ii)">
<p class="indent-3" data-title="50.24(a)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> The intervention under investigation must be administered before consent from the subjects' legally authorized representatives is feasible; and</p>
</div>
<div id="p-50.24(a)(2)(iii)">
<p class="indent-3" data-title="50.24(a)(2)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> There is no reasonable way to identify prospectively the individuals likely to become eligible for participation in the clinical investigation.</p>
</div>
</div>
<div id="p-50.24(a)(3)">
<p class="indent-2" data-title="50.24(a)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> Participation in the research holds out the prospect of direct benefit to the subjects because:</p>
<div id="p-50.24(a)(3)(i)">
<p class="indent-3" data-title="50.24(a)(3)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Subjects are facing a life-threatening situation that necessitates intervention;</p>
</div>
<div id="p-50.24(a)(3)(ii)">
<p class="indent-3" data-title="50.24(a)(3)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Appropriate animal and other preclinical studies have been conducted, and the information derived from those studies and related evidence support the potential for the intervention to provide a direct benefit to the individual subjects; and</p>
</div>
<div id="p-50.24(a)(3)(iii)">
<p class="indent-3" data-title="50.24(a)(3)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Risks associated with the investigation are reasonable in relation to what is known about the medical condition of the potential class of subjects, the risks and benefits of standard therapy, if any, and what is known about the risks and benefits of the proposed intervention or activity.</p>
</div>
</div>
<div id="p-50.24(a)(4)">
<p class="indent-2" data-title="50.24(a)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> The clinical investigation could not practicably be carried out without the waiver.</p>
</div>
<div id="p-50.24(a)(5)">
<p class="indent-2" data-title="50.24(a)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> The proposed investigational plan defines the length of the potential therapeutic window based on scientific evidence, and the investigator has committed to attempting to contact a legally authorized representative for each subject within that window of time and, if feasible, to asking the legally authorized representative contacted for consent within that window rather than proceeding without consent. The investigator will summarize efforts made to contact legally authorized representatives and make this information available to the IRB at the time of continuing review.</p>
</div>
<div id="p-50.24(a)(6)">
<p class="indent-2" data-title="50.24(a)(6)"><span class="paragraph-hierarchy"><span class="paren">(</span>6<span class="paren">)</span></span> The IRB has reviewed and approved informed consent procedures and an informed consent document consistent with <a href="/current/title-21/section-50.25" class="cfr external">§ 50.25</a>. These procedures and the informed consent document are to be used with subjects or their legally authorized representatives in situations where use of such procedures and documents is feasible. The IRB has reviewed and approved procedures and information to be used when providing an opportunity for a family member to object to a subject's participation in the clinical investigation consistent with <a href="/current/title-21/section-50.24#p-50.24(a)(7)(v)" class="cfr external">paragraph (a)(7)(v)</a> of this section.</p>
</div>
<div id="p-50.24(a)(7)">
<p class="indent-2" data-title="50.24(a)(7)"><span class="paragraph-hierarchy"><span class="paren">(</span>7<span class="paren">)</span></span> Additional protections of the rights and welfare of the subjects will be provided, including, at least:</p>
<div id="p-50.24(a)(7)(i)">
<p class="indent-3" data-title="50.24(a)(7)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Consultation (including, where appropriate, consultation carried out by the IRB) with representatives of the communities in which the clinical investigation will be conducted and from which the subjects will be drawn;</p>
</div>
<div id="p-50.24(a)(7)(ii)">
<p class="indent-3" data-title="50.24(a)(7)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Public disclosure to the communities in which the clinical investigation will be conducted and from which the subjects will be drawn, prior to initiation of the clinical investigation, of plans for the investigation and its risks and expected benefits;</p>
</div>
<div id="p-50.24(a)(7)(iii)">
<p class="indent-3" data-title="50.24(a)(7)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study, including the demographic characteristics of the research population, and its results;</p>
</div>
<div id="p-50.24(a)(7)(iv)">
<p class="indent-3" data-title="50.24(a)(7)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Establishment of an independent data monitoring committee to exercise oversight of the clinical investigation; and</p>
</div>
<div id="p-50.24(a)(7)(v)">
<p class="indent-3" data-title="50.24(a)(7)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> If obtaining informed consent is not feasible and a legally authorized representative is not reasonably available, the investigator has committed, if feasible, to attempting to contact within the therapeutic window the subject's family member who is not a legally authorized representative, and asking whether he or she objects to the subject's participation in the clinical investigation. The investigator will summarize efforts made to contact family members and make this information available to the IRB at the time of continuing review.</p>
</div>
</div>
</div>
<div id="p-50.24(b)">
<p class="indent-1" data-title="50.24(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> The IRB is responsible for ensuring that procedures are in place to inform, at the earliest feasible opportunity, each subject, or if the subject remains incapacitated, a legally authorized representative of the subject, or if such a representative is not reasonably available, a family member, of the subject's inclusion in the clinical investigation, the details of the investigation and other information contained in the informed consent document. The IRB shall also ensure that there is a procedure to inform the subject, or if the subject remains incapacitated, a legally authorized representative of the subject, or if such a representative is not reasonably available, a family member, that he or she may discontinue the subject's participation at any time without penalty or loss of benefits to which the subject is otherwise entitled. If a legally authorized representative or family member is told about the clinical investigation and the subject's condition improves, the subject is also to be informed as soon as feasible. If a subject is entered into a clinical investigation with waived consent and the subject dies before a legally authorized representative or family member can be contacted, information about the clinical investigation is to be provided to the subject's legally authorized representative or family member, if feasible.</p>
</div>
<div id="p-50.24(c)">
<p class="indent-1" data-title="50.24(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> The IRB determinations required by <a href="/current/title-21/section-50.24#p-50.24(a)" class="cfr external">paragraph (a)</a> of this section and the documentation required by <a href="/current/title-21/section-50.24#p-50.24(e)" class="cfr external">paragraph (e)</a> of this section are to be retained by the IRB for at least 3 years after completion of the clinical investigation, and the records shall be accessible for inspection and copying by FDA in accordance with <a href="/current/title-21/section-56.115#p-56.115(b)" class="cfr external">§ 56.115(b) of this chapter</a>.</p>
</div>
<div id="p-50.24(d)">
<p class="indent-1" data-title="50.24(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> Protocols involving an exception to the informed consent requirement under this section must be performed under a separate investigational new drug application (IND) or investigational device exemption (IDE) that clearly identifies such protocols as protocols that may include subjects who are unable to consent. The submission of those protocols in a separate IND/IDE is required even if an IND for the same drug product or an IDE for the same device already exists. Applications for investigations under this section may not be submitted as amendments under <a href="/current/title-21/section-312.30" class="cfr external">§§ 312.30</a> or <a href="/current/title-21/section-812.35" class="cfr external">812.35 of this chapter</a>.</p>
</div>
<div id="p-50.24(e)"><p class="indent-1" data-title="50.24(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> If an IRB determines that it cannot approve a clinical investigation because the investigation does not meet the criteria in the exception provided under <a href="/current/title-21/section-50.24#p-50.24(a)" class="cfr external">paragraph (a)</a> of this section or because of other relevant ethical concerns, the IRB must document its findings and provide these findings promptly in writing to the clinical investigator and to the sponsor of the clinical investigation. The sponsor of the clinical investigation must promptly disclose this information to FDA and to the sponsor's clinical investigators who are participating or are asked to participate in this or a substantially equivalent clinical investigation of the sponsor, and to other IRB's that have been, or are, asked to review this or a substantially equivalent investigation by that sponsor.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/61-FR-51528" class="fr-reference" data-reference="61 FR 51528">61 FR 51528</a>, Oct. 2, 1996]
</p>
</div>

<div class="section" id="50.25">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.25","citation":"21 CFR 50.25"}'>§ 50.25 Elements of informed consent.</h4>
<div id="p-50.25(a)">
<p class="indent-1" data-title="50.25(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Basic elements of informed consent.</em>  In seeking informed consent, the following information shall be provided to each subject:</p>
<div id="p-50.25(a)(1)">
<p class="indent-2" data-title="50.25(a)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental.</p>
</div>
<div id="p-50.25(a)(2)">
<p class="indent-2" data-title="50.25(a)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> A description of any reasonably foreseeable risks or discomforts to the subject.</p>
</div>
<div id="p-50.25(a)(3)">
<p class="indent-2" data-title="50.25(a)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> A description of any benefits to the subject or to others which may reasonably be expected from the research.</p>
</div>
<div id="p-50.25(a)(4)">
<p class="indent-2" data-title="50.25(a)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject.</p>
</div>
<div id="p-50.25(a)(5)">
<p class="indent-2" data-title="50.25(a)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained and that notes the possibility that the Food and Drug Administration may inspect the records.</p>
</div>
<div id="p-50.25(a)(6)">
<p class="indent-2" data-title="50.25(a)(6)"><span class="paragraph-hierarchy"><span class="paren">(</span>6<span class="paren">)</span></span> For research involving more than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained.</p>
</div>
<div id="p-50.25(a)(7)">
<p class="indent-2" data-title="50.25(a)(7)"><span class="paragraph-hierarchy"><span class="paren">(</span>7<span class="paren">)</span></span> An explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a research-related injury to the subject.</p>
</div>
<div id="p-50.25(a)(8)">
<p class="indent-2" data-title="50.25(a)(8)"><span class="paragraph-hierarchy"><span class="paren">(</span>8<span class="paren">)</span></span> A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.</p>
</div>
</div>
<div id="p-50.25(b)">
<p class="indent-1" data-title="50.25(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Additional elements of informed consent.</em>  When appropriate, one or more of the following elements of information shall also be provided to each subject:</p>
<div id="p-50.25(b)(1)">
<p class="indent-2" data-title="50.25(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable.</p>
</div>
<div id="p-50.25(b)(2)">
<p class="indent-2" data-title="50.25(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent.</p>
</div>
<div id="p-50.25(b)(3)">
<p class="indent-2" data-title="50.25(b)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> Any additional costs to the subject that may result from participation in the research.</p>
</div>
<div id="p-50.25(b)(4)">
<p class="indent-2" data-title="50.25(b)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject.</p>
</div>
<div id="p-50.25(b)(5)">
<p class="indent-2" data-title="50.25(b)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject.</p>
</div>
<div id="p-50.25(b)(6)">
<p class="indent-2" data-title="50.25(b)(6)"><span class="paragraph-hierarchy"><span class="paren">(</span>6<span class="paren">)</span></span> The approximate number of subjects involved in the study.</p>
</div>
</div>
<div id="p-50.25(c)">
<p class="indent-1" data-title="50.25(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> When seeking informed consent for applicable clinical trials, as defined in <a href="https://www.govinfo.gov/link/uscode/42/282" class="usc external" target="_blank" rel="noopener noreferrer">42 U.S.C. 282(j)(1)(A)</a>, the following statement shall be provided to each clinical trial subject in informed consent documents and processes. This will notify the clinical trial subject that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank under paragraph (j) of section 402 of the Public Health Service Act. The statement is: “A description of this clinical trial will be available on <em><a href="http://www.ClinicalTrials.gov" class="external" target="_blank" rel="noopener noreferrer">http://www.ClinicalTrials.gov</a>,</em> as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”</p>
</div>
<div id="p-50.25(d)">
<p class="indent-1" data-title="50.25(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> The informed consent requirements in these regulations are not intended to preempt any applicable Federal, State, or local laws which require additional information to be disclosed for informed consent to be legally effective.</p>
</div>
<div id="p-50.25(e)"><p class="indent-1" data-title="50.25(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> Nothing in these regulations is intended to limit the authority of a physician to provide emergency medical care to the extent the physician is permitted to do so under applicable Federal, State, or local law.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/46-FR-8951" class="fr-reference" data-reference="46 FR 8951">46 FR 8951</a>, Jan. 27, 1981, as amended at <a href="https://www.federalregister.gov/citation/76-FR-270" class="fr-reference" data-reference="76 FR 270">76 FR 270</a>, Jan. 4, 2011]
</p>
</div>

<div class="section" id="50.27">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.27","citation":"21 CFR 50.27"}'>§ 50.27 Documentation of informed consent.</h4>
<div id="p-50.27(a)">
<p class="indent-1" data-title="50.27(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> Except as provided in <a href="/current/title-21/section-56.109#p-56.109(c)" class="cfr external">§ 56.109(c)</a>, informed consent shall be documented by the use of a written consent form approved by the IRB and signed and dated by the subject or the subject's legally authorized representative at the time of consent. A copy shall be given to the person signing the form.</p>
</div>
<div id="p-50.27(b)">
<p class="indent-1" data-title="50.27(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> Except as provided in <a href="/current/title-21/section-56.109#p-56.109(c)" class="cfr external">§ 56.109(c)</a>, the consent form may be either of the following:</p>
<div id="p-50.27(b)(1)">
<p class="indent-2" data-title="50.27(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> A written consent document that embodies the elements of informed consent required by <a href="/current/title-21/section-50.25" class="cfr external">§ 50.25</a>. This form may be read to the subject or the subject's legally authorized representative, but, in any event, the investigator shall give either the subject or the representative adequate opportunity to read it before it is signed.</p>
</div>
<div id="p-50.27(b)(2)"><p class="indent-2" data-title="50.27(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> A <em>short form</em> written consent document stating that the elements of informed consent required by <a href="/current/title-21/section-50.25" class="cfr external">§ 50.25</a> have been presented orally to the subject or the subject's legally authorized representative. When this method is used, there shall be a witness to the oral presentation. Also, the IRB shall approve a written summary of what is to be said to the subject or the representative. Only the short form itself is to be signed by the subject or the representative. However, the witness shall sign both the short form and a copy of the summary, and the person actually obtaining the consent shall sign a copy of the summary. A copy of the summary shall be given to the subject or the representative in addition to a copy of the short form.</p></div>
</div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/46-FR-8951" class="fr-reference" data-reference="46 FR 8951">46 FR 8951</a>, Jan. 27, 1981, as amended at <a href="https://www.federalregister.gov/citation/61-FR-57280" class="fr-reference" data-reference="61 FR 57280">61 FR 57280</a>, Nov. 5, 1996]
</p>
</div>

</div>

<div class="subpart" id="subpart-C"><h2 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-50/subpart-C&quot;,&quot;citation&quot;:&quot;21 CFR Part 50 Subpart C&quot;}">Subpart C [Reserved]</h2>
</div>

<div class="subpart" id="subpart-D"><h2 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-50/subpart-D&quot;,&quot;citation&quot;:&quot;21 CFR Part 50 Subpart D&quot;}">Subpart D—Additional Safeguards for Children in Clinical Investigations</h2>

<div class="source"><h4 class="inline-header">Source:</h4><p class="inline-paragraph"><a href="https://www.federalregister.gov/citation/66-FR-20598" class="fr-reference" data-reference="66 FR 20598">66 FR 20598</a>, Apr. 24, 2001, unless otherwise noted.
</p></div>
<div class="section" id="50.50">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.50","citation":"21 CFR 50.50"}'>§ 50.50 IRB duties.</h4>
<p>In addition to other responsibilities assigned to IRBs under this <a href="/current/title-21/part-56" class="cfr external">part and part 56 of this chapter</a>, each IRB must review clinical investigations involving children as subjects covered by this subpart D and approve only those clinical investigations that satisfy the criteria described in <a href="/current/title-21/section-50.51" class="cfr external">§ 50.51</a>, <a href="/current/title-21/section-50.52" class="cfr external">§ 50.52</a>, or <a href="/current/title-21/section-50.53" class="cfr external">§ 50.53</a> and the conditions of all other applicable sections of this subpart D.</p>
</div>

<div class="section" id="50.51">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.51","citation":"21 CFR 50.51"}'>§ 50.51 Clinical investigations not involving greater than minimal risk.</h4>
<p>Any clinical investigation within the scope described in <a href="/current/title-21/section-50.1" class="cfr external">§§ 50.1</a> and <a href="/current/title-21/section-56.101" class="cfr external">56.101 of this chapter</a> in which no greater than minimal risk to children is presented may involve children as subjects only if the IRB finds that:</p>
<div id="p-50.51(a)">
<p class="indent-1" data-title="50.51(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> No greater than minimal risk to children is presented; and</p>
</div>
<div id="p-50.51(b)"><p class="indent-1" data-title="50.51(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> Adequate provisions are made for soliciting the assent of the children and the permission of their parents or guardians as set forth in <a href="/current/title-21/section-50.55" class="cfr external">§ 50.55</a>.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/78-FR-12951" class="fr-reference" data-reference="78 FR 12951">78 FR 12951</a>, Feb. 26, 2013]
</p>
</div>

<div class="section" id="50.52">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.52","citation":"21 CFR 50.52"}'>§ 50.52 Clinical investigations involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects.</h4>
<p>Any clinical investigation within the scope described in <a href="/current/title-21/section-50.1" class="cfr external">§§ 50.1</a> and <a href="/current/title-21/section-56.101" class="cfr external">56.101 of this chapter</a> in which more than minimal risk to children is presented by an intervention or procedure that holds out the prospect of direct benefit for the individual subject, or by a monitoring procedure that is likely to contribute to the subject's well-being, may involve children as subjects only if the IRB finds that:</p>
<div id="p-50.52(a)">
<p class="indent-1" data-title="50.52(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> The risk is justified by the anticipated benefit to the subjects;</p>
</div>
<div id="p-50.52(b)">
<p class="indent-1" data-title="50.52(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> The relation of the anticipated benefit to the risk is at least as favorable to the subjects as that presented by available alternative approaches; and</p>
</div>
<div id="p-50.52(c)"><p class="indent-1" data-title="50.52(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> Adequate provisions are made for soliciting the assent of the children and permission of their parents or guardians as set forth in <a href="/current/title-21/section-50.55" class="cfr external">§ 50.55</a>.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/66-FR-20598" class="fr-reference" data-reference="66 FR 20598">66 FR 20598</a>, Apr. 24, 2001, as amended at <a href="https://www.federalregister.gov/citation/78-FR-12951" class="fr-reference" data-reference="78 FR 12951">78 FR 12951</a>, Feb. 26, 2013]
</p>
</div>

<div class="section" id="50.53">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.53","citation":"21 CFR 50.53"}'>§ 50.53 Clinical investigations involving greater than minimal risk and no prospect of direct benefit to individual subjects, but likely to yield generalizable knowledge about the subjects' disorder or condition.</h4>
<p>Any clinical investigation within the scope described in <a href="/current/title-21/section-50.1" class="cfr external">§§ 50.1</a> and <a href="/current/title-21/section-56.101" class="cfr external">56.101 of this chapter</a> in which more than minimal risk to children is presented by an intervention or procedure that does not hold out the prospect of direct benefit for the individual subject, or by a monitoring procedure that is not likely to contribute to the well-being of the subject, may involve children as subjects only if the IRB finds that:</p>
<div id="p-50.53(a)">
<p class="indent-1" data-title="50.53(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> The risk represents a minor increase over minimal risk;</p>
</div>
<div id="p-50.53(b)">
<p class="indent-1" data-title="50.53(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> The intervention or procedure presents experiences to subjects that are reasonably commensurate with those inherent in their actual or expected medical, dental, psychological, social, or educational situations;</p>
</div>
<div id="p-50.53(c)">
<p class="indent-1" data-title="50.53(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> The intervention or procedure is likely to yield generalizable knowledge about the subjects' disorder or condition that is of vital importance for the understanding or amelioration of the subjects' disorder or condition; and</p>
</div>
<div id="p-50.53(d)"><p class="indent-1" data-title="50.53(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> Adequate provisions are made for soliciting the assent of the children and permission of their parents or guardians as set forth in <a href="/current/title-21/section-50.55" class="cfr external">§ 50.55</a>.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/66-FR-20598" class="fr-reference" data-reference="66 FR 20598">66 FR 20598</a>, Apr. 24, 2001, as amended at <a href="https://www.federalregister.gov/citation/78-FR-12951" class="fr-reference" data-reference="78 FR 12951">78 FR 12951</a>, Feb. 26, 2013]
</p>
</div>

<div class="section" id="50.54">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.54","citation":"21 CFR 50.54"}'>§ 50.54 Clinical investigations not otherwise approvable that present an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children.</h4>
<p>If an IRB does not believe that a clinical investigation within the scope described in <a href="/current/title-21/section-50.1" class="cfr external">§§ 50.1</a> and <a href="/current/title-21/section-56.101" class="cfr external">56.101 of this chapter</a> and involving children as subjects meets the requirements of <a href="/current/title-21/section-50.51" class="cfr external">§ 50.51</a>, <a href="/current/title-21/section-50.52" class="cfr external">§ 50.52</a>, or <a href="/current/title-21/section-50.53" class="cfr external">§ 50.53</a>, the clinical investigation may proceed only if:</p>
<div id="p-50.54(a)">
<p class="indent-1" data-title="50.54(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> The IRB finds that the clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; and</p>
</div>
<div id="p-50.54(b)">
<p class="indent-1" data-title="50.54(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> The Commissioner of Food and Drugs, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, education, ethics, law) and following opportunity for public review and comment, determines either:</p>
<div id="p-50.54(b)(1)">
<p class="indent-2" data-title="50.54(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> That the clinical investigation in fact satisfies the conditions of <a href="/current/title-21/section-50.51" class="cfr external">§ 50.51</a>, <a href="/current/title-21/section-50.52" class="cfr external">§ 50.52</a>, or <a href="/current/title-21/section-50.53" class="cfr external">§ 50.53</a>, as applicable, or</p>
</div>
<div id="p-50.54(b)(2)">
<p class="indent-2" data-title="50.54(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> That the following conditions are met:</p>
<div id="p-50.54(b)(2)(i)">
<p class="indent-3" data-title="50.54(b)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children;</p>
</div>
<div id="p-50.54(b)(2)(ii)">
<p class="indent-3" data-title="50.54(b)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> The clinical investigation will be conducted in accordance with sound ethical principles; and</p>
</div>
<div id="p-50.54(b)(2)(iii)"><p class="indent-3" data-title="50.54(b)(2)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Adequate provisions are made for soliciting the assent of children and the permission of their parents or guardians as set forth in <a href="/current/title-21/section-50.55" class="cfr external">§ 50.55</a>.</p></div>
</div>
</div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/66-FR-20598" class="fr-reference" data-reference="66 FR 20598">66 FR 20598</a>, Apr. 24, 2001, as amended at <a href="https://www.federalregister.gov/citation/78-FR-12951" class="fr-reference" data-reference="78 FR 12951">78 FR 12951</a>, Feb. 26, 2013]
</p>
</div>

<div class="section" id="50.55">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.55","citation":"21 CFR 50.55"}'>§ 50.55 Requirements for permission by parents or guardians and for assent by children.</h4>
<div id="p-50.55(a)">
<p class="indent-1" data-title="50.55(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> In addition to the determinations required under other applicable sections of this subpart D, the IRB must determine that adequate provisions are made for soliciting the assent of the children when in the judgment of the IRB the children are capable of providing assent.</p>
</div>
<div id="p-50.55(b)">
<p class="indent-1" data-title="50.55(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> In determining whether children are capable of providing assent, the IRB must take into account the ages, maturity, and psychological state of the children involved. This judgment may be made for all children to be involved in clinical investigations under a particular protocol, or for each child, as the IRB deems appropriate.</p>
</div>
<div id="p-50.55(c)">
<p class="indent-1" data-title="50.55(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> The assent of the children is not a necessary condition for proceeding with the clinical investigation if the IRB determines:</p>
<div id="p-50.55(c)(1)">
<p class="indent-2" data-title="50.55(c)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> That the capability of some or all of the children is so limited that they cannot reasonably be consulted, or</p>
</div>
<div id="p-50.55(c)(2)">
<p class="indent-2" data-title="50.55(c)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> That the intervention or procedure involved in the clinical investigation holds out a prospect of direct benefit that is important to the health or well-being of the children and is available only in the context of the clinical investigation.</p>
</div>
</div>
<div id="p-50.55(d)">
<p class="indent-1" data-title="50.55(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> Even where the IRB determines that the subjects are capable of assenting, the IRB may still waive the assent requirement if it finds and documents that:</p>
<div id="p-50.55(d)(1)">
<p class="indent-2" data-title="50.55(d)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> The clinical investigation involves no more than minimal risk to the subjects;</p>
</div>
<div id="p-50.55(d)(2)">
<p class="indent-2" data-title="50.55(d)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> The waiver will not adversely affect the rights and welfare of the subjects;</p>
</div>
<div id="p-50.55(d)(3)">
<p class="indent-2" data-title="50.55(d)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> The clinical investigation could not practicably be carried out without the waiver; and</p>
</div>
<div id="p-50.55(d)(4)">
<p class="indent-2" data-title="50.55(d)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> Whenever appropriate, the subjects will be provided with additional pertinent information after participation.</p>
</div>
</div>
<div id="p-50.55(e)">
<p class="indent-1" data-title="50.55(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> In addition to the determinations required under other applicable sections of this subpart D, the IRB must determine, in accordance with and to the extent that consent is required under part 50, that the permission of each child's parents or guardian is granted.</p>
<div id="p-50.55(e)(1)">
<p class="indent-2" data-title="50.55(e)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Where parental permission is to be obtained, the IRB may find that the permission of one parent is sufficient for clinical investigations to be conducted under <a href="/current/title-21/section-50.51" class="cfr external">§ 50.51</a> or <a href="/current/title-21/section-50.52" class="cfr external">§ 50.52</a>.</p>
</div>
<div id="p-50.55(e)(2)">
<p class="indent-2" data-title="50.55(e)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Where clinical investigations are covered by <a href="/current/title-21/section-50.53" class="cfr external">§ 50.53</a> or <a href="/current/title-21/section-50.54" class="cfr external">§ 50.54</a> and permission is to be obtained from parents, both parents must give their permission unless one parent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child.</p>
</div>
</div>
<div id="p-50.55(f)">
<p class="indent-1" data-title="50.55(f)"><span class="paragraph-hierarchy"><span class="paren">(</span>f<span class="paren">)</span></span> Permission by parents or guardians must be documented in accordance with and to the extent required by <a href="/current/title-21/section-50.27" class="cfr external">§ 50.27</a>.</p>
</div>
<div id="p-50.55(g)"><p class="indent-1" data-title="50.55(g)"><span class="paragraph-hierarchy"><span class="paren">(</span>g<span class="paren">)</span></span> When the IRB determines that assent is required, it must also determine whether and how assent must be documented.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/66-FR-20598" class="fr-reference" data-reference="66 FR 20598">66 FR 20598</a>, Apr. 24, 2001, as amended at <a href="https://www.federalregister.gov/citation/78-FR-12951" class="fr-reference" data-reference="78 FR 12951">78 FR 12951</a>, Feb. 26, 2013]
</p>
</div>

<div class="section" id="50.56">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-50.56","citation":"21 CFR 50.56"}'>§ 50.56 Wards.</h4>
<div id="p-50.56(a)">
<p class="indent-1" data-title="50.56(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> Children who are wards of the State or any other agency, institution, or entity can be included in clinical investigations approved under <a href="/current/title-21/section-50.53" class="cfr external">§ 50.53</a> or <a href="/current/title-21/section-50.54" class="cfr external">§ 50.54</a> only if such clinical investigations are:</p>
<div id="p-50.56(a)(1)">
<p class="indent-2" data-title="50.56(a)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Related to their status as wards; or</p>
</div>
<div id="p-50.56(a)(2)">
<p class="indent-2" data-title="50.56(a)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Conducted in schools, camps, hospitals, institutions, or similar settings in which the majority of children involved as subjects are not wards.</p>
</div>
</div>
<div id="p-50.56(b)">
<p class="indent-1" data-title="50.56(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> If the clinical investigation is approved under <a href="/current/title-21/section-50.56#p-50.56(a)" class="cfr external">paragraph (a)</a> of this section, the IRB must require appointment of an advocate for each child who is a ward.</p>
<div id="p-50.56(b)(1)">
<p class="indent-2" data-title="50.56(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> The advocate will serve in addition to any other individual acting on behalf of the child as guardian or in loco parentis.</p>
</div>
<div id="p-50.56(b)(2)">
<p class="indent-2" data-title="50.56(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> One individual may serve as advocate for more than one child.</p>
</div>
<div id="p-50.56(b)(3)">
<p class="indent-2" data-title="50.56(b)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> The advocate must be an individual who has the background and experience to act in, and agrees to act in, the best interest of the child for the duration of the child's participation in the clinical investigation.</p>
</div>
<div id="p-50.56(b)(4)"><p class="indent-2" data-title="50.56(b)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> The advocate must not be associated in any way (except in the role as advocate or member of the IRB) with the clinical investigation, the investigator(s), or the guardian organization.</p></div>
</div>
</div>

</div>
</div><script type="application/json" id="source-and-authority-data">{"origins":[{"level":"part","identifier":"50","label_level":"Part 50","hierarchy":{"title":"21","chapter":"I","subchapter":"A","part":"50"},"current":true,"authority":["\u003ca href=\"https://www.govinfo.gov/link/uscode/21/321\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e21 U.S.C. 321\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/343\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e343\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/346\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e346\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/346a\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e346a\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/348\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e348\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/350a\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e350a\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/350b\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e350b\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/352\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e352\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/353\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e353\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/355\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e355\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/360\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e360\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/360c\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e360c-360f\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/360h\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e360h-360j\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/371\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e371\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/379e\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e379e\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/381\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e381\u003c/a\u003e; \u003ca href=\"https://www.govinfo.gov/link/uscode/42/216\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e42 U.S.C. 216\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/42/241\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e241\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/42/262\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e262\u003c/a\u003e.\n"],"source":["\u003ca href=\"https://www.federalregister.gov/citation/45-FR-36390\" class=\"fr-reference\" data-reference=\"45 FR 36390\"\u003e45 FR 36390\u003c/a\u003e, May 30, 1980, unless otherwise noted.\n"],"link":"/current/title-21/part-50","title":"Part 50"}]}</script>

</div><div class="seal-block seal-block-footer"><h6>eCFR Content</h6></div></div>      </div>
    </div>
  </div>
</div>

        </div>
      </div>
    </div>

    <div class="site-footer container-fluid" id="footer">
  <div class="container">
    <div class="col-xs-12 col-md-12">
      <div class="row">
        <div class="col-xs-3 col-md-3">
          <h2>Pages</h2>
          <ul class="list with-bullets">
            <li><a href="/">Home</a></li>
            <li><a href="/">Titles</a></li>
            <li><a href="/search">Search</a></li>
            <li><a href="/recent-changes">Recent Changes</a></li>
            <li><a href="/corrections">Corrections</a></li>
          </ul>
        </div>

        <div class="col-xs-3 col-md-3">
          <h2>Reader Aids</h2>
          <ul class="list with-bullets">
              <li>
                <a href="https://www.ecfr.gov/reader-aids/using-ecfr">Using the eCFR Point-in-Time System</a>
              </li>
              <li>
                <a href="https://www.ecfr.gov/reader-aids/understanding-the-ecfr">Understanding the eCFR</a>
              </li>
              <li>
                <a href="https://www.ecfr.gov/reader-aids/government-policy-and-ofr-procedures">Government Policy and OFR Procedures</a>
              </li>
              <li>
                <a href="https://www.ecfr.gov/reader-aids/ecfr-developer-resources">Developer Resources</a>
              </li>
          </ul>
        </div>
        <div class="col-xs-3 col-md-3">
          <h2>Information</h2>
          <ul class="list with-bullets">
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/about-this-site">About This Site</a></li>
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/about-this-site#legal-status">Legal Status</a></li>
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/privacy">Privacy</a></li>
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/accessibility">Accessibility</a></li>
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/foia">FOIA</a></li>
            <li><a href="https://www.archives.gov/eeo/policy/no-fear-notice.html">No Fear Act</a></li>
            <li><a href="https://www.archives.gov/federal-register/contact.html#coop">Continuity Information</a></li>
          </ul>
        </div>

        <div class="col-xs-3 col-md-3">
          <h2>My eCFR</h2>
          <ul class="list with-bullets">
            <li>
              <a href="/my/subscriptions">My Subscriptions</a>
            </li>
            <li>
              <a data-turbo="false" href="https://www.ecfr.gov/auth/sign_in?jwt=eyJhbGciOiJIUzI1NiJ9.eyJub3RpZmljYXRpb25zIjp7ImluZm8iOiJZb3Ugd2lsbCBiZSByZWRpcmVjdGVkIGJhY2sgdG8gdGhlIGVDRlIgYWZ0ZXIgeW91IGhhdmUgc2lnbmVkIGluIG9yIGNyZWF0ZWQgYW4gYWNjb3VudC4ifX0.-sYkHWfC02yb0CpuUqmPkxxnF0yzlNHaS5520hYIUy8&amp;redirect_to=https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50">Sign In / Sign Up</a>
            </li>
          </ul>
        </div>


      </div>
    </div>
  </div>
</div>

</body></html>
